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ABSTRACT 
 
Harriet L. Arrington, DDS: Inducible Nitric Oxide Synthase and Periodontal Inflammation:              
A Preclinical Canine Study. 
(Under the direction of Dr. David Paquette, Dr. Andre Mol, and Dr. Ray Williams) 
 
Up-regulation of inducible nitric oxide synthase (iNOS) has been linked to 
periodontal disease and its progression. This preclinical study was therefore 
conducted to evaluate the effects of a selective iNOS inhibitor, INO-1001, on the 
initiation and progression of experimental gingivitis in the canine model.  Following a 
safety and feasibility study, eighteen beagles were randomized to treatment with 
topically administered INO-1001 or placebo gels and experimental gingivitis was 
induced over an 8-week period. Clinical outcomes (i.e., plaque index, ginigival index, 
bleeding on probing and modified sulcular bleeding index) were measured at 
baseline, 4 and 8 weeks. No inter-group differences were noted at the baseline or 4-
week examinations. At the 8-week exam, measures of gingival inflammation and 
sulcular ulceration were significantly increased in the INO-1001 group compared to 
placebo. These results suggest that iNOS may play a dual role in the pathogenesis of 
periodontal disease and may be critical for periodontal homeostasis.  
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1. INTRODUCTION 
Periodontal disease, encompassing both gingivitis and periodontitis, is a host- 
mediated inflammatory process initiated by oral bacterial insult which may result in 
significant alterations in the normal structure and/or function of the supporting tissues of the 
dentition. Although colonization of host tissues by pathogenic organisms is the initiating 
factor in this disease process, the associated rate of progression and degree of destruction are 
dependent upon both the virulence of the invading organisms and the magnitude/persistence 
of the host response to this infection.  
The initial response of the human host to subgingival microbial infection is an innate 
immuno-inflammatory reaction primarily directed by gingival epithelial cells and 
polymorphonuclear leukocytes (PMNs). If this process is ineffective in the elimination of 
invading pathogens, then various immune and inflammatory cells are recruited to the area, a 
multitude of cytotoxic and inflammatory mediators are released, and multiple enzyme 
systems are activated, ultimately resulting in enhanced inflammation and tissue destruction. 
The amplitude of this inflammatory response is dependent upon the genetic profile of the 
microorganism and the host, as well as related environmental factors.1 Depending upon the 
extent of inflammation and destruction, resultant changes in the periodontium may become 
irreversible. Moreover if left untreated, the disease process can lead to chronic inflammation, 
extensive compromise of periodontal support with resultant changes in the dentition, and 
repeated systemic exposure to periodontal pathogens.2-4 This repeated systemic bacterial 
exposure and resultant inflammatory response may play a significant role, either directly or 
2indirectly, in the pathogenesis of many systemic diseases and their sequelae. To date, 
periodontal disease has been linked to a variety of systemic disease states and conditions 
including: cardiovascular disease5,6, cerebrovascular disease7,8, diabetes9,10, the delivery of 
pre-term, low birth weight infants11-13, and most recently, pancreatic cancer14. Due to the 
significant morbidity and mortality associated with these conditions, the importance of 
prevention, diagnosis, and effective treatment of periodontal disease may increasingly be 
appreciated from a systemic health perspective. 
As can be recognized from the above introduction to periodontal disease, 
modification of host-pathogen interactions are of paramount importance in the prevention 
and treatment of this disease process as well as its subsequent sequelae. Historically the vast 
majority of treatments have focused on the subgingival microbiota and its elimination or 
alteration via mechanical or chemotherapeutic modalities. These interventions have been 
demonstrated to be quite effective in disease management; however, in a significant portion 
of the population they have proved inadequate in halting disease progression.15 Thus, recent 
studies have primarily been directed at modification of the host’s contribution to this disease 
process. The inhibition of a variety of key mediators have been investigated with several 
showing promise in preclinical and/or clinical trials. One such mediator, nitric oxide, is 
currently receiving much attention due to its association with multiple chronic inflammatory 
processes, including periodontal disease, and will be the principal focus of this thesis. 
 
32. OBJECTIVES 
 
The current study was designed with the objectives of: 1) evaluating the feasibility 
and safety of topical and systemic administration of three novel iNOS inhibitors in 
experimental gingivitis and periodontitis; 2) testing the hypothesis that over-expression of 
iNOS is detrimental to the periodontal tissues; and therefore, its inhibition should lessen the 
extent and severity of gingival inflammation in the canine model of gingivitis; and 
conversely, 3) testing the alternative hypothesis that iNOS is essential for periodontal 
homeostasis and serves a protective role during this disease process.  
 
43.  BACKGROUND AND SIGNIFICANCE  
 
To understand the complexities of modifying host-pathogen interactions, a basic 
appreciation of the nature of the sub-gingival microbiota and host immune response is 
necessary. Therefore, a brief review of current knowledge regarding these topics, as well as a 
discussion of the collective and individual contributions of key cells and mediators to the 
pathogenesis of periodontal disease will be presented. A summary of key host modulatory 
therapies, pertinent findings and limitations will also be described with specific focus on 
inhibition of nitric oxide synthase, the enzyme responsible for nitric oxide production. 
 Although nitric oxide is essential for homeostasis and immunity, its production via 
the inducible isoform of nitric oxide synthase (iNOS) has repeatedly been implicated in 
periodontal disease and its progression. Furthermore, inhibition of nitric oxide synthesis in 
animal models of both experimental gingivitis and periodontitis has been shown to be 
beneficial.  
 
3.1  PERIODONTAL MICROBIOTA 
Although the relationship of plaque and calculus to periodontal disease has been 
appreciated since ancient times, the relationship of microbes to this picture was not 
recognized until the late 1600’s. Anton van Leeuwenhoek in 1683 first described the 
microscopic presence of a vast array of “animalcules”, or microorganisms, in dental plaque.16 
5Since this time, there has been significant interest in determining the nature of these 
microorganisms and their relationship with disease.  
The contributions from multiple microbiologic studies in the 1960’s and 1970’s have 
greatly enhanced our understanding of the nature and composition of subgingival plaque. 
These studies described not only trends of compositional shifts in the microflora during the 
transition from periodontal health to disease, such as an increasingly Gram-negative, 
anaerobic, and motile profile, but they also noted that specific organisms appeared to 
frequently be associated with the presence of disease.17-20 Furthermore during this time 
period, our knowledge of the structure of subgingival plaque was greatly enhanced by 
investigations of bacterial communities in other aqueous environments. Reports of the 
existence and early characterization of bacterial “biofilms” facilitated the recognition that 
sub-gingival plaque was not the chance accumulation of bacteria and debris, but instead, was 
the result of formation of highly structured bacterial communities.21-23 It has subsequently 
been established that the sub-gingival bacterial biofilm forms via rather specific bacterial 
interactions and microbial successions.24-26 This biofilm has been shown to exhibit nutritional 
co-operation, environmental modification (i.e., oxygen detoxification), small-molecule 
signal-mediated gene regulation, gene transfer, and enhanced resistance to host defenses and 
antimicrobials.21-23 
Many studies have been conducted in the isolation and characterization of various 
subgingival microbes in an attempt to determine which bacteria are likely associated with the 
pathogenesis of periodontal disease. In 1998, Socransky categorized bacteria which had been 
isolated from subgingival plaque samples into groups, which not only loosely represented the 
sequence of colonization of these organisms in the periodontal pocket and their relationships 
6with one another, but also represented the relative association of the organisms with the 
pathogenesis of periodontal disease.27 In Socransky’s description of these subgingival 
microbial complexes, the “orange” and “red” complexes both consisted of organisms 
commonly associated with disease, with the “red” complex organisms being those most 
strongly related to clinical parameters of inflammation and periodontal destruction.25 The 
organisms in the “orange complex” consist of Fusobacterium nucleatum, F. periodonticum,
Prevotella intermedia, P. nigrescens, Peptostreptococcus micros, Campylobacter rectus, C. 
showae, C. gracilis, Eubacterium nodatum, and Streptococcus contsellatus, and these 
organisms predominantly constitute the loosely adherent plaque found between the tooth-
associated and epithelial pocket-associated plaque in the periodontal pocket.25,26 The “red 
complex” organisms are found to be spatially associated with the subgingival epithelium and 
comprise the majority of the pocket-associated plaque.26 These organisms include 
Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia.25-28 Although not 
included in Socransky’s model due to the population studied, Actinobacillus 
actinomycetemcomitans is also frequently associated with periodontal disease, especially 
localized aggressive forms, and has also been classified as a periodontal pathogen.29 
The bacteria that are currently recognized as “periodontal pathogens” include A. 
actinomycetemcomitans (Aa), P. gingivalis (Pg), and T. forsythia (Tf).29 These organisms 
have been consistently associated with periodontitis and its progression, and have been 
shown to possess a variety of factors which allow them to significantly modify the immuno-
inflammatory response and promote tissue destruction.29 These factors include components 
such as lipopolysaccharides, peptidoglycans, lipoteichoic acids, fimbriae, proteases, heat 
shock proteins, formyl-methionyl peptides, and cytotoxins.30 These allow bacteria to adhere 
7to and invade host tissues, regulate the host immune response, and ultimately result in host 
defense evasion, bacterial persistence, and enhanced host tissue destruction.30 
Although considerable progress has been made in characterization of the subgingival 
biofilm, much has yet to be understood.  It has been estimated that over 400 different 
bacterial species may inhabit the subgingival periodontal pocket, and of these organisms, less 
than half have been cultured.31 We, therefore, currently have a very limited picture of the true 
nature of the microbial composition, interactions, and virulence factors associated with the 
subgingival biofilm.  Also, at this time, the mechanisms by which these bacteria interact with 
the host to elicit the immune response have not been fully elucidated. The recent discoveries 
of a variety of non-specific pathogen recognition receptors (PRRs) in mammalian cells has 
provided a greater understanding of the nature of host-microbial interactions.32-34 These 
receptors have the capacity for non-specific recognition of potential pathogens based upon 
highly conserved molecular patterns present in a variety of microbial components. The PRRs 
in humans are currently known to include Toll-like receptors (TLRs), Nod-like receptors 
(NLRs), and helicase domain-containing antiviral proteins.35 Although the roles of several of 
these receptors have yet to be fully defined, the types and quantities of mediators released 
during an infection will, in large part, depend upon the differential stimulation of these 
receptors. Due to expression of these PRRs by the majority of cell types, rather than only by 
those of myeloid or lymphoid origin, these findings have demonstrated a possibility for 
extensive interactions between the innate and adaptive immune response and have 
established a potential role for a variety of cells in the host immune response.  
Although an appreciation of the subgingival bacterial biofilm is essential in 
understanding the pathogenesis of periodontal disease, it is insufficient to explain the 
8variability in disease expression and severity among patients. Host susceptibility, due to 
defects in one or more aspects of the host response, has been identified as an essential 
component for periodontal disease progression.1 It has therefore been established that “the 
periodontopathic bacterial flora is necessary but not sufficient for disease.”1
3.2  HOST RESPONSE IN PERIODONTAL DISEASE 
Host response refers to the recognition, activation, and subsequent regulation of an 
individual’s immune response to the presence of an antigenic or foreign substance. This 
response is generally an immuno-inflammatory process aimed at the eradication of the 
offending microorganism. However, the immune system of an individual also has the 
capability of suppressing this response which is important for preventing the recognition of 
“self” proteins as well as maintaining colonization by various beneficial, or commensal, 
organisms. Although currently not fully understood, this immunosuppressive mechanism, 
known as tolerance, is essential for the prevention of host cell recognition and inappropriate 
activation of the immune response. However, some pathogenic bacteria may take advantage 
of this mechanism to prevent host detection and permit invasion and replication within host 
tissues.  
The first line of defense of the gingival sulcus, or crevice, against bacterial insult 
relies on both the structural integrity and physiologic nature of the crevice. The presence of 
an intact sulcular epithelium acts as a physical barrier in preventing the penetration of 
bacteria and bacterial products into the epithelium, underlying tissues, and systemic 
circulation. The gingival crevicular fluid (GCF), which is an exudate derived from the serum 
of adjacent blood vessels, aids in “flushing” bacteria and their products from the base of the 
9crevice outward into the oral environment. Also depending upon the level of disease present, 
the GCF may contain substances such as immunoglobulins, complement, cytokines, 
antimicrobial peptides, immune and bacterial cells, enzymes, and metabolic byproducts.36 
The turnover or shedding of the crevicular epithelium is also important in helping to prevent 
both bacterial colonization and invasion. Additionally in health, the termination of the 
junctional epithelium, which comprises the base of the sulcus, is at or above the 
cementoenamel junction. The tooth surface that opposes the sulcular epithelium is therefore 
composed entirely of enamel, which, in contrast to the cemental covering of the root surface, 
is considerably less plaque retentive and prone to bacterial contamination.37, 38 
Assuming these primary defense mechanisms are adequate, no further response is 
required by the host; however, if the bacterial flora is sufficiently pathogenic, or the host is at 
an increased susceptibility to invasion due to various genetic or environmental factors, the 
help of phagocytic cells in the innate immune response is elicited. 
In otherwise healthy individuals, the initial immune response to a pathogenic 
subgingival flora is one that is dominated by polymorphonuclear leukocytes (PMNs), or 
neutrophils. Even in health, PMNs are present in periodontal tissues and serve in a 
surveillance capacity, where they are found just beneath or migrating through the junctional 
epithelium into the sulcus. Although previously thought to only participate in the immune 
response via their barrier function, it has been demonstrated that the gingival epithelial cells 
are capable of recognizing pathogens via expression of PRRs (TLRs 2, 3, 4, 5, 6 and 9) and 
are able to produce and release  defensins, interleukin-8 (IL-8), IL-1, tumor necrosis 
factor- (TNF-), IL-6, lipopolysaccharide binding protein (LBP), matrix metalloproteinases 
(MMPs) and nitric oxide based upon the microbial stimulus.39-41 These mediators are able to 
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provide a strong chemotactic gradient to enhance the migration of PMNs into the gingival 
sulcus and activate other underlying cells such as mast cells, dendritic cells, macrophages, 
etc.39-41 The infiltrating PMNs may become activated via direct interactions with bacteria and 
bacterial by-products or cytokines produced from resident cells. These activated PMNs are 
not only involved in the phagocytosis and killing of bacteria, but also release a variety of 
cytokines, chemokines, and inflammatory mediators, which are responsible for the further 
recruitment and priming of immune and inflammatory cells. In addition to PMNs, other local 
immune cells may also become activated via direct interactions with bacterial antigens or 
cytokines. According to the stimulus, these cells then release various pro-inflammatory and 
chemotactic molecules (i.e., TNF-, interferon-, IL-1, IL-6, IL-8, IL-12, leukotriene B4, NO, 
prostaglandin E2, histamine, monocyte chemoattractant protein-1, monocyte chemoattractant 
protein-5, monocyte inflammatory protein-1a, and monocyte inflammatory protein-2) that, 
among other things, facilitate the infiltration of even larger numbers of immuno-
inflammatory cells into the area. PGE2, TNF-, NO and histamine cause vasodilation and 
increase vascular permeability. The resultant compromise in vascular integrity aids in cell 
migration from the peripheral circulation as well as escape of intravascular fluid and proteins 
(i.e., immunoglobulins) into the surrounding tissues, resulting in edema and increased GCF 
production. In addition, the expression of E-selectin and P-selectin on the endothelium of the 
blood vessels and up-regulation of glycoproteins and intercellular adhesion molecule (I-
CAM) on the PMNs facilitate diapedesis and migration of these cells out of the circulation 
and into the tissues. Furthermore, a family of enzymes known as the matrix 
metalloproteinases (MMPs) are produced and activated during this process. The MMPs are 
involved in the destruction of collagen and other extracellular matrix (ECM) components, 
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creating space for newly recruited immune cells. The recruited PMNs migrate through the 
junctional epithelium and densely aggregate along the surface of the sulcular epithelium. 
These PMNs primarily act to eliminate bacteria by means of phagocytosis. Additionally, the 
recruitment of monocytes and activation of macrophages play a significant role in bacterial 
phagocytosis and elimination in addition to the perpetuation of the inflammatory response. 
The production of complement and other acute phase reactants by hepatocytes, activation of 
the complement cascade and release of cytotoxic mediators also aids in bacterial clearance. 
Concomitant with this innate immune response, bacterial antigens recognized by TLRs on 
the dendritic cell may induce it to undergo a morphogenetic change, converting it from a 
stationary phagocytic cell to a mobile antigen-presenting cell (APC), which then can migrate 
to local and regional lymph nodes to activate the adaptive immune response. If bacterial 
clearance is achieved at this point, the immune response is quelled, and the local 
inflammation and tissue destruction are reversed. However, if this is not accomplished and 
the host response continues to escalate, the adaptive immune response with the associated 
activation of T and B lymphocytes begins to dominate. As this process continues, it becomes 
increasingly more complex with the involvement of a variety of cell types, the production 
and release of a multitude of mediators, and the contribution of various enzymes, mediators, 
and immune modulators by the pathogenic bacteria. Meanwhile, the zone and extent of tissue 
destruction increases.1, 37-40, 42-44 
3.2.1 CELLS OF THE PERIODONTAL INFLAMMATORY RESPONSE 
The cells active in periodontal disease pathogenesis are those that comprise the 
periodontium (epithelial cells, fibroblasts, osteoblasts, osteoclasts) and those classically 
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associated with the immune response (neutrophils, monocytes/macrophages, dendritic cells, 
lymphocytes). In an attempt to protect the host, these cells must maintain a delicate balance 
between pro- and anti-inflammatory actions, and any dysregulation in this balance may result 
in either an exuberant, host-destructive response or hypo-responsiveness that predisposes the 
host to infection.  
Fibroblasts are the predominant cell type in the periodontium and are responsible for 
the normal synthesis and turnover of the extracellular matrix, within which the cells live and 
function.37,38  This matrix is important for cellular migration, retention of pro-enzymes, 
growth factors, and other molecules involved in the response to tissue injury and wound 
healing.37,38  One of the major components of the extracellular matrix is collagen, and the 
regulation of its synthesis and breakdown by fibroblasts is essential for periodontal health. 
Fibroblasts have been found to play an active role in host immunity and tissue destruction. 
They express TLRs 2 and 4 (PDL fibroblasts also express TLR-9) and respond to a variety of 
microbial factors in addition to multiple cytokines and mediators.39, 40 Dependent upon the 
stimulus, these cells can produce chemokines (IL-8, MCP-1), cytokines (IL-1, TNF-), 
lipid mediators (PGE2), nitric oxide, adhesion molecules (ICAM-1) and enzymes that 
degrade the extracellular matrix (MMPs).39-41, 45, 46 In addition, gingival and PDL fibroblasts 
can express receptor activator of nuclear factor kappa B ligand (RANKL) following bacterial 
stimulation.47-49 Due to the abundant nature of these cells and their ability to produce 
substances which have been highly linked to breakdown of the hard and soft tissues of the 
periodontium (IL-1, TNF-, PGE2, MMPs, RANKL), fibroblasts likely play a critical role 
in the manifestations of periodontal disease as well as subsequent wound healing.47, 50-54 
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As briefly described above, PMNs, or neutrophils, are the first of the leukocytic 
immune cells to respond to infection and may kill bacteria or influence their growth via: 1) 
delivery of reactive oxygen and nitrogen species during “respiratory burst” 2) secretion of 
cytoplasmic granule contents, 3) phagocytosis by engulfment into phagosomes, or 4) death or 
apoptosis resulting in a release of intracellular contents.37,55 The “respiratory burst” process 
has classically been viewed to involve the production of high levels of superoxide and other 
reactive oxygen species. However, it has lately been recognized that during this process NO 
is also produced by the iNOS enzyme and contributes to the ability of PMNs and 
macrophages to efficiently kill microorganisms.41,56-58 In addition to their phagocytic 
function, these cells are also able to secrete cytoplasmic granule contents containing 
antimicrobial products and tissue destructive enzymes.59 Neutrophils have been shown to 
possess all of the Toll-like receptors (with the exception of TLR-3), and accordingly are able 
to be stimulated by a wide variety of microbial products. The interaction of microbes, by-
products, cytokines, and mediators with their corresponding cellular receptors determine the 
neutrophil’s response (i.e., production of reactive oxygen species, NO, MMPs, IL-1, TNF-,
PGE2, etc).40 It has repeatedly been demonstrated that the proper functioning of these cells is 
essential for maintenance of periodontal health. Defects in neutrophil number, chemotaxis, 
adhesion, migration, bacterial killing efficiency, production of cytokines, NO, and enzymes 
have all been related to periodontal disease and tissue destruction.60-65 
Macrophages constitute from 5 to 30% of the infiltrating cells in inflamed periodontal 
lesions.42 Generally, low numbers of macrophages are recruited into the gingival sulcus; 
however, if neutrophils are inefficient in microbial clearance or bacteria/ bacterial products 
invade host tissues, the contribution of macrophages to the immune response increases. 
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Macrophages are phagocytic cells which have important functions in microbial clearance, 
antigen presentation, and enhancement of the inflammatory response. 
Monocytes/macrophages express TLRs 1, 2, 4, 5, and 6 and RANK on their surface and 
release an extensive array of chemokines and inflammatory mediators (IL-8, MIP-1, MCP-5, 
TNF-a, IL-1, IL-12, IL-6, IFN-, PGE2, NO).39, 42, 66 Furthermore, these cells have been 
shown to have enhanced activity as APCs following exposure to RANKL, a mediator which 
is elevated in periodontitis lesions.46, 67, 68 Similar to neutrophils, macrophages have also been 
implicated in host destruction. They have been shown to be the primary cells producing IL-1 
in inflamed gingival tissues and a hyperinflammatory response by these cells has been noted 
in periodontitis patients.69, 70 Due to the inflammatory nature of the macrophage response, 
these cells are thought to be important not only in periodontal disease, but also in the 
enhanced inflammatory response seen in obesity, diabetes, and atherosclerosis.10, 71-73 
Dendritic cells are stationary phagocytic cells located beneath the epithelium which 
represent a major link between the innate and adaptive immune response. The expression of 
different TLRs upon dendritic cells is dependent upon their lineage (myeloid or 
plasmacytoid) and their location; however, upon stimulation, these cells may release various 
mediators, express co-stimulatory molecules on their surface, migrate to regional lymph 
nodes, present antigens to naïve T lymphocytes, and  activate the adaptive immune response.  
Mature dendritic cells express a high level of RANK as well, which is thought to possibly 
enhance interactions between the dendritic cell and RANKL expressing T lymphocyte during 
antigen presentation.40, 74 
The adaptive immune response is a lymphocytic response distinct from the earlier 
innate response by antigen specificity and memory. Adaptive immunity is subdivided into 
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cellular and humoral branches as follows. The cellular immune response is dominated by T 
lymphocytes while the humoral response is predominately a B lymphocytic response. Upon 
antigen presentation, the type of response elicited is dependent upon the nature of stimulus, 
co-stimulatory molecules present on the APC and cytokines/mediators released. The T 
lymphocytes are comprised by helper T cells (Th or CD4+), cytotoxic T cells (Tc or CD8+), 
and memory T cells (Tm). The helper T cells are further differentiated by the types of 
mediators that they release and type of adaptive response that they promote. The  type 1 
helper T cell (Th1) primarily releases IL-2 and IFN- and stimulates a Tc mediated response, 
the type 2 helper T cell (Th2) releases IL-4, IL-5, IL-6, IL-10, and IL-13 and stimulates the 
differentiation of B lymphocytes into plasma cells, whereas the type 3 regulatory  T cells 
(Th3 or Treg) down-regulate the immune response. Cytotoxic T cells are involved with direct 
killing of infected host cells and thus, target intracellular pathogens, while B 
lymphocytes/plasma cells are of prime importance in the elimination of extracellular 
pathogens. Plasma cells produce antigen specific antibodies which neutralize bacterial 
products, activate the complement cascade, promote aggregation and clumping of bacteria, 
and promote opsonization of bacteria to enhance phagocytosis.66Although an effective 
adaptive immune response is critical for host health and survival, the presence of a chronic 
lymphocytic infiltrate is generally associated with periodontal tissue breakdown. It has 
classically been stated that the predominance of B cells/ plasma cells in the periodontium is 
associated with the conversion of gingivitis to periodontitis, and therefore, also to the 
initiation of alveolar bone loss.75-77 This finding has recently been supported to some extent 
by the finding that over 90% of B lymphocytes in the inflammatory infiltrate of periodontitis 
lesions express RANKL, a potent stimulator of osteoclastogenesis. Although T lymphocytes 
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also express RANKL, a much lower percentage of cells have been shown to express this 
ligand.46, 78 Another relatively recent finding that may further implicate lymphocytes in 
periodontal destruction is the presence of nictotine receptors on T and B lymphocytes.79, 
80This finding may provide further understanding of the biologic mechanisms linking 
smoking and periodontal disease on both a local and systemic level. Despite multiple studies 
on the relationship between lymphocytes and periodontal disease, the roles of the different 
lymphocytes, their relative proportions, and the importance of their presence during different 
stages of periodontal disease are issues that remain quite controversial.  
 
3.2.2 CYTOKINES AND OTHER INFLAMMATORY MEDIATORS 
Cytokines are small protein mediators which constitute the principal mechanism of 
cellular communication. Cytokines released by cells are capable of acting in an autocrine 
and/or paracrine manner to influence cellular activity. Upon binding to their receptors, the 
actions of each of these signaling molecules will be dependent upon the cell and receptor 
which are stimulated, as well as the summation or cancellation of signals resulting from other 
mediators. The cytokines of greatest interest during the inflammatory response are IL-1, IL-
6, and TNF-.42, 81 
The interleukins are a group of cytokines so named due to their production by, and 
involvement in, the cellular signaling of leukocytes. Although many interleukins play an 
important role in the immuno-inflammatory response via both pro- and anti-inflammatory 
mechanisms, the interleukins which have been most closely associated with an enhanced 
inflammatory response and subsequent tissue destruction are IL-1 and IL-6.  
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Interleukin-1 is a pro-inflammatory cytokine that is an important regulator of the host 
innate response and is recognized as one of the most significant mediators of tissue 
destruction in cases of periodontitis.81 It was discovered in periodontally involved gingival 
tissues by Horton in 1972 and termed “osteoclast activating factor” (OAF) due to its ability 
to induce osteoclast activation and bone resorption.50 OAF was later identified by Dewhirst 
to be interleukin-1.82 IL-1 is synthesized primarily by macrophages and monocytes; 
however, it is also produced by keratinocytes, dendritic cells, neutrophils and fibroblasts.81 It 
is a potent stimulator of connective tissue catabolism and acts synergistically with TNF- to 
stimulate bone resorption and inhibit bone formation.54, 83 Additionally, IL-1 induces the 
release of large quantities of PGE2 and MMPs by fibroblasts and monocytes.81, 84 
Interleukin-6 is a cytokine which influences various aspects of the immune response 
and inflammatory reactions. It is primarily produced by activated monocytes, fibroblasts, and 
endothelial cells, and to a lesser extent by activated macrophages, T and B lymphocytes, 
osteoblasts and keratinocytes. Major functions of IL-6 include the induction of B cell 
maturation into plasma cells, stimulation of antibody secretion, and differentiation of 
cytotoxic T cells. IL-6 has also been suggested to play an important role in stimulation of 
osteoclastogenesis and bone resorption as well the induction of acute phase reactant 
production by hepatocytes (in conjunction with IL-1 and TNF-).42, 85, 86 
TNF- is a pro-inflammatory cytokine that is primarily secreted by monocytes and 
macrophages. It induces the secretion of collagenase by fibroblasts, activates osteoclastic 
bone resorption, and induces the synthesis of IL-1 and PGE2 in fibroblasts and 
macrophages.42, 87-89 In addition to its previously mentioned synergistic actions with IL-1 and 
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IL-6 in the induction of bone resorption and production of acute phase reactants, TNF- also 
acts synergistically with IL-1 and IFN- to potently induce nitric oxide production.83, 90 
Other mediators of significance in the pathogenesis of periodontal disease include 
arachadonic acid metabolites, matrix metalloproteinases, and reactive oxygen and nitrogen 
species.  
The arachadonic acid metabolites are lipid mediators derived from the cleavage of 
membrane phospholipids by phospholipase A2 and subsequent enzymatic modification by 
lipooxygenase (LO) or cylcooxygenase (COX). These metabolites have been shown to play 
important roles in chemotaxis and mediation of the immune response. In the presence of 
lipooxygenase, arachadonic acid (AA) is converted to leukotrienes or 
hydroxyeicosatetraenoic acids (HETEs). However, in the presence of cyclooxygenase-1 or 
cyclooxygenase-2 (COX-1 or COX-2), AA undergoes enzymatic conversion to prostaglandin 
H2 (PGH2), which is then further metabolized to one of at least five prostanoids: PGE2,
prostaglandin I2 (PGI2 or prostacyclin), prostaglandin F2 (PGF2), prostaglandin D2 (PGD2), or 
thromboxane A2 (TXA2).91 These prostanoids have a variety of biologic actions including 
effects on vascular tone, cardiovascular function, platelet aggregation, renal function, and 
bone turnover. Although cyclooxygenase-1 and cyclooxygenase-2 have similar biochemical 
activity in converting arachadonic acid to PGH2 in vitro, the ultimate prostanoids they 
produce in vivo may be different due to differential regulation of COX-1 and COX-2, tissue 
distribution, and availability of the prostanoid synthases.91 Prostaglandin E2 and leukotriene 
B4 (LTB4) are two of the most highly implicated arachadonic acid metabolites in the 
progression of periodontal disease. LTB4 is predominantly produced by activated neutrophils 
and is a potent chemotactic stimulus for the further recruitment of neutrophils and 
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monocytes. PGE2 on the other hand is produced mainly by activated monocytes, fibroblasts, 
neutrophils and platelets and mediates vasodilation and vascular permeability, induces MMP 
secretion by monocytes and fibroblasts, and is a powerful inducer of osteoclastic bone 
resorption.81, 84, 91-94 
MMPs are a family of zinc and calcium dependent enzymes that are responsible for 
the degradation of most extracellular matrix proteins during various physiologic processes 
such as fetal development, growth, tissue remodeling/repair and angiogenesis.91 There are 
three major groups of MMPs: 1) the collagenases; 2) the gelatinases; and 3) the 
stromelysins.91 These enzymes can be produced by a variety of cells (i.e., fibroblasts, 
neutrophils, keratinocytes, macrophages, endothelial cells, mast cells, etc.), and their activity 
can be regulated by natural inhibitors present in the tissues and serum (tissue inhibitors of 
metalloproteinases, -macroglobulins). In general, MMPs are induced temporarily in 
response to exogenous signals such as various pathogenic substances, cytokines, growth 
factors, and cell matrix interactions. The expression and activity of matrix metalloproteinases 
in adult tissues is normally low, but is significantly up-regulated in various pathologic and 
inflammatory conditions.91 As with other inflammatory processes, up-regulation of MMP 
expression has been demonstrated in patients with gingivitis and periodontitis.95-97 TNF-,
IL-1, and PGE2 appear to be the main signals for MMP synthesis by gingival fibroblasts, and 
subsequent host tissue destruction.81, 91,98 
Reactive oxygen species (ROS), such as superoxide, hydroxyl radicals, hydrogen 
peroxide, and hypochlorous acid play an important role in the microbicidal activity of 
phagocytes and mediate a variety of signaling pathways.55 Their endogenous production is 
primarily due to leakage from mitochondrial electron transport chain and NADPH-oxidase 
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activation during the respiratory burst process of phagocytic cells.55, 99 The stimulation of 
superoxide production by PMNs and macrophages can be triggered by a variety of antigens, 
cytokines and mediators as well as the activation of Toll-like receptors by bacterial 
products.99 Superoxide is a free radical which can rapidly cause cellular damage via 
oxidation of lipids and proteins.99 Therefore, superoxide produced within the cell is quickly 
converted to hydrogen peroxide, a less toxic metabolite, by the enzyme superoxide dismutase 
(SOD). Superoxide dismutase has three principal forms, one found in the cytosol, one in the 
mitochondria, and one found extracellularly.99 These enzymes have one of the highest 
reaction constants known in biologic systems which allows for the rapid dismutation of 
superoxide and prevention of cellular injury.100 However, if the production of superoxide is 
excessive, SOD activity is decreased, or NO is produced in close proximity to superoxide, 
the reaction of these two molecules to form peroxynitrite, a molecule with even higher 
toxicity and potential for host tissue damage, may occur.100 
Reactive nitrogen species (RNS) consist of the nitric oxide free radical and its 
products (nitric oxide, nitrite, peroxynitrite, nitroxyl and nitrosonium). NO is produced by a 
wide variety of cells and appears to be an important regulator of various physiologic 
processes in both animals and humans.100 As with several other biologic mediators, this 
regulation appears to be affected not only by the presence of nitric oxide, but also by its 
relative concentrations and the presence of other mediators/cytokines. In addition, NO 
imbalances have been noted in a variety of chronic infectious and inflammatory conditions 
including periodontal disease.65, 90, 101-103 
The above cytokines and mediators work in concert, and often synergistically, to up-
regulate the local inflammatory response, induce the release of acute phase reactants from 
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hepatocytes, and enhance periodontal destruction. Elevated levels of these pro-inflammatory/ 
host destructive mediators (IL-1, IL-6, TNF-, PGE2, MMPs, ROS, RNS) have been found 
not only to be important in animal models, but have also been reported in the gingival 
crevicular fluid and gingival tissue samples of patients with periodontal disease.53, 92, 97, 104-110 
Greater elevations are generally noted in sites with active periodontal breakdown, while their 
concentrations following periodontal therapy have been shown to decline.52, 111-121 The 
plausibility of periodontal destruction resulting from chronic high levels of these substances 
is further supported by the fact that bacteria of the subgingival biofilm have been shown to 
elicit their production in host cells. For example, lipopolysaccharide (LPS), a highly 
immunogenic component of Gram-negative bacteria, has been shown to be a potent inducer 
of IL-1, IL-6, TNF-, PGE2, MMP, ROS, and NO production via its interaction with TLR-4 
which is expressed on the surface of cells comprising the periodontium as well as those 
involved in the immune response (epithelial cells, fibroblasts, osteoblasts/osteoclasts, 
endothelial cells, neutrophils, macrophages, dendritic cells, mast cells, etc.).39, 40, 87 
3.3  NITRIC OXIDE: OVERVIEW 
Nitric oxide (NO) is a gaseous, free radical, biologic signaling molecule which can 
readily diffuse through the cytoplasm and plasma membranes due to its solubility in both 
aqueous and lipid environments.100 Its importance as a biologic mediator and the complex 
nature of its interactions have begun to be recognized in a multitude physiologic 
processes.122-125 Most of the biologic actions attributable to NO are achieved by increasing 
intracellular cyclic guanosine monophosphate (cGMP) concentrations via binding and 
activation of soluble guanylyl cyclase; however, NO can also covalently bond with free thiol 
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groups of proteins and thiol containing free amino acids such as cysteine. Through the 
formation of nitrosothiols, NO may modify enzyme activity and possibly regulate various 
metabolic processes, including glycolysis and mitochondrial respiration.100 
NO is generated within biologic tissues via the enzymatic conversion of L-arginine 
to L-citrulline by nitric oxide synthase (NOS). This enzyme exists in the body as three 
distinct isoforms: neuronal (nNOS or NOS-I), inducible (iNOS or NOS-II) and endothelial 
NOS (eNOS or NOS-III).126 There is also some evidence that a fourth NOS isoform may be 
present in mitochondria (mtNOS); however, there is still considerable debate on its 
existence.127-129 These isoforms have historically been categorized based upon differences in 
their primary locations in the body, inducibility, levels of nitric oxide production upon 
activation, and calcium dependence. Neuronal NOS and endothelial NOS are expressed 
constitutively, are calcium dependent and produce low levels of NO upon stimulation. 
Conversely, iNOS is regulated at the transcriptional level and is shown to be induced in 
multiple cell types upon bacterial or cytokine stimulation. Inducible NOS produces high 
levels of NO upon stimulation, reaches its maximal activity after approximately 24 hours, 
and is active at low calcium concentrations.100 Despite these differences, the NOS isoforms 
are all quite similar in their structure, consisting of both oxygenase and reductase domains, 
and their requirement of L-arginine and key cofactors for activity (FAD, FMN, NADPH, 
calmodulin, tetrahydrobiopterin (BH4), and heme).100 In response to insufficient availability 
of these factors (i.e., L-arginine or BH4 deficiency), an uncoupling of the oxygenase and 
reductase domains may occur and result in the production of reactive oxygen species such as 
superoxide and hydrogen peroxide.100 
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Nitric oxide has been found to have various roles in the normal physiology and 
pathophysiology of multiple biologic processes. It assumes a critical role in the regulation of 
vascular tone, smooth muscle proliferation, angiogenesis, coagulation, mitochondrial energy 
generation, neurotransmission, immunity, cell survival, and wound healing.130-135 Conversely, 
nitric oxide as well as peroxynitrite have also been implicated in various inflammatory 
conditions such as arthritis, lupus, diabetes, cardiovascular disease, stroke, Alzheimer’s 
disease, shock, multiple sclerosis and inflammatory bowel diseases.136-138 
Most of the pathologies associated with NO are most often attributable to 
peroxynitrite, a powerful oxidant formed from the reaction of nitric oxide with superoxide. 
During infection and inflammation, significant quantities of both superoxide and nitric oxide
can be produced by cells of the immune system.100 When produced in relatively high
quantities and in close approximation to one another, these molecules rapidly react to form
peroxynitrite by a non-enzymatic reaction. Although superoxide dismutase (SOD), which is
present in the cytoplasm, can rapidly breakdown superoxide, the rate of the reaction for the
formation of peroxynitrite is approximately four times faster than the reaction of superoxide 
with superoxide dismutase.100, 139 Formation of peroxynitrite can result in both oxidative and 
nitrosative stress since it consists of both a reactive oxygen and a reactive nitrogen species. 
Peroxynitrite has been shown to induce lipid peroxidation, damage proteins and nucleic 
acids, and result in DNA strand breaks.140 Furthermore, it has been suggested that in an 
attempt to repair DNA damage, the enzyme poly-ADP ribose polymerase (PARP) is 
activated, resulting in depletion of nuclear adenosine triphosphate (ATP) stores and 
ultimately leading to cellular necrosis.140 Since sufficient ATP stores are necessary for cells 
to undergo apoptosis, and thus limit the exposure of surrounding tissues to intracellular 
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enzymes, inflammatory mediators and toxins, the activation of PARP ultimately results in 
enhanced tissue destruction.141-143 
Due to the ubiquitous nature of the biologic interactions involving NO and the 
apparent deleterious consequences of its dysregulation, the control of NO occurs upon many 
levels. Splice variants of all human NOSs have been found which decrease or obliterate NOS 
activity.126, 144, 145 NO is regulated by feedback inhibition, the presence of endogenous NOS 
inhibitors such as asymmetric dimethylarginine (ADMA), and enzymes which compete for 
the substrate L-arginine (i.e., arginase).129 Moreover, the availability of L-arginine and 
necessary NOS cofactors, the presence of compounds which readily bind NO (heme, 
glutathione), and the modulation of transcription and translation of NOS by deoxyribonucleic 
acid (DNA) methylation or by actions of various cytokines and mediators also are involved 
in the regulation of nitric oxide production.100, 126, 146 
 
3.3.1  NITRIC OXIDE AND HOMEOSTASIS 
 Although the importance of nitric oxide has been demonstrated in a variety of 
biologic processes, those most pertinent to the discussion of periodontal disease include the 
effects of nitric oxide on the development, maintenance, and proper functioning of the bone, 
vasculature and immune response. 
Evidence of the importance of NO in bone formation and remodeling has come from 
the observations of defective bone formation, volume, turnover, and osteoblast function in 
eNOS and iNOS deficient mice.147-150 Interpretation of results from studies regarding the 
effects of nitric oxide on bone metabolism has been somewhat difficult in the past due to the 
presence and frequency of conflicting results. However, it is now understood that there is a 
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phasic response to NO in bone metabolism.151 The presence of constitutive and inducible 
forms of NOS have been demonstrated in both osteoblasts and osteoclasts.152 Osteoblasts 
have been shown to produce a low basal level of NO which is important for normal function. 
Significant increases or decreases in NO production via inflammatory stimuli or NOS 
inhibitors have been found to inhibit osteoblast proliferation and differentiation, and in some 
cases, result in apoptosis.153-155 Low NO levels also appear to be important for the normal 
function of osteoclasts. If NO production is abolished or significantly increased, then bone 
resorption ceases under normal conditions. However, NO produced by iNOS also serves as 
an autocrine negative feedback signal that regulates osteoclastogenesis.156-158 Furthermore, 
high NO levels appear to antagonize the effects of PGE2 on bone resorption, whereas low 
levels appear to act in synergy in enhancing bone resorption.159 Therefore, in the presence of 
inflammatory or pro-osteoclastic mediators, the inhibition of iNOS may result in significantly 
increased bone resorption.151, 152 
The critical relationship of NO to vascular homeostasis was not recognized until the 
1980’s when Furchgott and coworkers discovered that the production of a chemical, which 
they termed “endothelium-derived relaxing factor” (ERDF), was the mechanism by which 
endothelial cells produced relaxation of vascular smooth muscle.160 It was subsequently 
determined that ERDF was the gaseous free radical, nitric oxide.123, 124 Since that discovery, 
research in the field of nitric oxide has increased exponentially. Both eNOS and iNOS have 
been demonstrated to be present in endothelial cells. Small amounts of eNOS have been 
found in platelets, and nNOS has been discovered in the nerve endings surrounding the 
vasculature as well as in the heart.161-164 Studies have shown that NO inhibits vascular smooth 
muscle proliferation, platelet aggregation, down-regulates endothelial adhesion molecules, 
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mediates vasodilation, and enhances angiogenesis in conjunction with IL-8 and VEGF.165-167 
Furthermore, it has been demonstrated that the ability of VEGF to stimulate angiogenesis is 
significantly impaired in the absence of eNOS.168 
Over almost two decades, the importance of nitric oxide in the immune response has 
been reported by numerous in vitro and in vivo studies. To date, nitric oxide’s role in 
immunity has been most extensively studied in the murine model due to the ready 
availability, short gestational period, relative inexpense, and ease of handling of this small 
mammalian model. The effects of NO are also more easily elucidated in this model due to the 
ability to create NOS knockout models as well as the ability to rather quickly assess the 
effects of pharmacologic NOS inhibition on both the animals and their offspring. Although 
significant differences exist in human and murine physiology, studies have demonstrated 
similar roles for NO in the immune responses of both mice and humans. NO has been found 
to play an essential role in TLR signaling in mice and it has been demonstrated that iNOS 
knockout mice have an impaired response to bacterial infection in addition to a decreased 
susceptibility to endotoxic shock (a LPS/TLR-4-mediated process).150, 169 Additionally, 
neutrophils and macrophages have been shown to possess both cNOS and iNOS, and the 
activity of these isoenzymes appears to be critical in the proper functioning of these cells 
(i.e., phagocytic activity, intracellular killing, and cell survival).  Furthermore, a basal level 
of NO produced in neutrophils by cNOS has been suggested to be important in neutrophil 
chemotaxis via a cGMP dependent mechanism. The up- or down-regulation of this NO 
production has been shown to significantly impair neutrophil chemotaxis.150, 170-172 
Researchers have also reported that nitric oxide  plays an important role in the killing 
or containment of intracellular pathogens and parasites such as Leishmania major, Giardia 
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lamblis, and Cryptococcus neoformans; however, the addition of superoxide and subsequent 
peroxynitrite formation has been shown to reduce toxicity against these organisms likely due 
to decreased NO levels.56-58, 173 In contrast, other microorganisms such as Escherichia coli, 
Salmonella Typhimurium, and Candida albicans appear to require the production of both 
oxygen and nitrogen free radicals by the host for maximal microbicidal activity.173-176 Also, 
induction of iNOS by IFN- is believed to be essential for protection from viral infection.177 
3.3.2  NITRIC OXIDE AND INFLAMMATION 
 Of the negative effects associated with nitric oxide, almost all are the result of an 
inflammatory process which is inappropriate in duration, severity or both. This inflammatory 
process leads to cellular destruction and ultimately results in tissue and organ dysfunction. 
One of the most frequently studied processes in which an acute up-regulation of iNOS is 
noted is that of septic shock. This is one of few acute disease states in which iNOS is 
implicated; however, this process gets much attention due to its high rate of mortality. During 
septic shock, the LPS of Gram-negative bacteria gains access to the systemic circulation and 
induces the production of massive quantities of NO, resulting in severe hypotension, poor 
tissue perfusion, organ failure, and ultimately death. There have been a number of studies 
which have implicated iNOS as the primary effector of this process, and still more have 
shown the benefits of NOS inhibition in animal models.178-185 Multiple studies have also 
shown an increase in iNOS activity in chronic inflammatory diseases such as arthritis, 
inflammatory bowel disease, multiple sclerosis, and periodontal disease.90,136-138,186 For 
example, serum and synovial fluid samples from patients with rheumatoid arthritis and 
osteoarthritis displayed enhanced formation of nitric oxide.186 Furthermore, in 
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immunolocalization studies, iNOS was found to be strongly expressed in the synovial lining, 
fibroblasts, endothelial cells, and local inflammatory cells of inflamed joints while its 
expression was conspicuously absent in samples from healthy patients.186-189 
Consistent with models of septic shock, NOS inhibition in animal models of arthritis, 
multiple slcerosis, and inflammatory bowel disease has also been found to diminish the 
associated inflammatory responses and suppress pathologic changes.190-192 Additionally, in 
diabetic animals, NOS inhibition has been shown to prevent the formation of advanced 
glycation end products (AGEs), which through interactions with their respective receptors 
(RAGEs), perpetuate the inflammatory response.193 
 
3.3.3  NITRIC OXIDE AND PERIODONTAL DISEASE 
 Substantial evidence also exists implicating NO in the pathogenesis of periodontal 
disease. LPS and other antigenic substances from putative periodontal pathogens such as A. 
actinomycetemcomitans, P. gingivalis, P. intermedia, P. nigrescens, and F. nucleatum have 
been shown to induce iNOS expression and NO production in murine macrophages.194-202 It 
has been demonstrated by human in vitro studies that iNOS expression and activity is 
induced in gingival fibroblasts and neutrophils following stimulation by periodontal 
pathogens, cytokines, and other inflammatory mediators.41, 203, 204 Also, neutrophils isolated 
from localized aggressive periodontitis patients were shown to display increased iNOS 
activity and subsequent chemotactic defects.170 Using the rat model of experimental 
periodontitis, Lohinai and Di Paola have both demonstrated the presence a low baseline level 
of iNOS expression in gingival tissues, which increased significantly following ligature 
placement.205, 206 These investigators also documented a parallel between the location and 
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degree of iNOS expression and the presence of 3-nitrotyrosine, a peroxynitrite reaction 
product, in gingivomucosal tissues of the study animals.205, 207, 208 Additionally, Lohinai and 
colleagues demonstrated the absence of 3-nitrotyrosine and iNOS expression in the sterile 
gingival tissues of rat pups.208 Similar studies examining the gingival tissues of human 
subjects with varying degrees of periodontal disease and periodontally healthy controls have 
also shown a strong relationship between iNOS expression, NO production, and the severity 
of inflammation and tissue destruction.104-106, 209-211 Matejka and co-workers found that levels 
of L-arginine and L-citrulline, the precursors and by-products of NO synthesis respectively, 
were increased in the gingival tissues of  patients with periodontitis as compared to healthy 
controls.105 Others have demonstrated increased iNOS expression/ activity in diseased human 
gingival tissues and gingival crevicular fluid by measuring levels of nitrate/nitrite,211 iNOS 
mRNA expression,104 or iNOS protein expression via immuno-histochemistry.106, 209-211 
Utilizing this last method, Batista and co-workers quantitatively evaluated iNOS expression 
in gingival samples from patients with clinically healthy gingival tissues, plaque induced 
gingivitis, and localized chronic periodontitis.210 Their findings demonstrated a significant 
increase in iNOS expression in gingivitis samples as compared to control. Expression was 
further increased in the samples from periodontitis patients.210 The results of the above in 
vitro and in vivo studies cumulatively suggest that: 1) Host iNOS expression and activity in 
the periodontium is the result of persistent microbial insult, 2) NO and peroxynitrite are 
significantly linked to host inflammatory changes in the periodontium, and 3) NO may play 
an important role in both host defense and disease pathogenesis. 
Following the presumption that iNOS up-regulation and subsequent peroxynitrite 
formation are detrimental to periodontal health via induction of DNA damage and PARP 
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activation, Lohinai and Di Paola have also investigated the involvement of PARP in 
periodontitis.142, 205,212 In male rat models of experimental periodontitis, both investigators 
have found increased levels of PARP in diseased gingival tissues and have shown benefits of 
its inhibition in decreasing associated vascular permeability and bone loss using the PARP 
inhibitors PJ34 and 5-AIQ.142, 205,212 
Equally important, several studies have demonstrated a protective function of NO, 
pointing to its role in bacterial killing and clearance of pathogenic organisms, as well as its 
possible anti-apoptic effects on PMNs.150, 211 Gyurko and coworkers found that NO is an 
important component of the immune response against the periodontal pathogen P. gingivalis.
In mice lacking iNOS, more severe infection developed and P. gingivalis clearance was 
decreased, despite enhanced production of superoxide by neutrophils. Additionally, they 
noted impaired PMN survival in the iNOS deficient mice.150 This protective role was further 
emphasized in a study by Skaleric wherein increased GCF nitrate/nitrite levels were 
associated with reductions in P. intermedia colony-forming units (CFU) in diabetic patients 
with periodontal disease.211 Carossa and colleagues in 2001 reported that oral NO production 
and salivary nitrite levels increased during de novo plaque deposition in periodontally healthy 
subjects. The authors proposed that this may be an early defense mechanism against bacterial 
proliferation in the dental plaque. They further demonstrated that this response was inhibited 
in smokers and was associated with an elevation in plaque bacterial counts as compared to 
non-smokers.213 
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4.  HOST MODULATION IN PERIODONTAL DISEASE MANAGEMENT   
 Despite the many virulence factors and potentially host destructive compounds 
identified from periodontal pathogens, current evidence points to the host’s immuno-
inflammatory response as the primary cause of periodontal tissue destruction. More 
specifically, the dysregulation or over-expression of the earlier mentioned cytokines, 
enzymes, and inflammatory mediators have been repeatedly recognized in human and animal 
models of gingivitis and periodontitis.  It is therefore reasonable that one of the areas of 
greatest research interest is in the modulation of inflammatory mediators for the treatment 
and prevention of periodontal disease. Primary avenues of host modulation which have been 
explored include inhibition of PGE2 production, osteoclast inhibition by bisphosphonates, 
antagonism of IL-1 and TNF-, inhibition of matrix metalloproteinases, the use of 
antioxidants/free radical scavengers, and inhibition of nitric oxide production.  
 
4.1  INHIBITION OF HOST INFLAMMATORY MEDIATORS 
 
Early studies on the modulation of periodontal disease by inhibition of specific 
pathology-associated host mediators (i.e., PGE2) were conducted by Nyman and Williams in 
the 1970’s and 1980’s. Using canine models, due to similarities in periodontal disease 
presentation and progression in canines and humans, these investigators were the first to 
evaluate the effects of prostaglandin synthesis inhibition on experimental and naturally 
occurring periodontitis. They discovered that the systemic administration of non-steroidal 
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anti-inflammatory drugs (NSAIDs) was effective in slowing periodontal disease progression 
and inhibiting alveolar bone loss.214-216 It has since been shown that a variety of NSAIDs 
(i.e., indomethacin, flurbiprofen, ibuprofen, ketoprofen, ketorolac, etc.) can lessen the extent 
of alveolar bone destruction and clinical attachment loss resulting from periodontitis.217, 217-
224 Furthermore, the mechanism of this protective action has been confirmed by GCF studies 
to be PGE2 synthesis inhibition.217, 225-228 It has long been recognized that aspirin and other 
NSAIDs exert the majority of their effects through the inhibition of the cyclooxygenase 
enzymes and thereby prevent the production of prostaglandins.229 Due to the well established 
relationship between PGE2 and periodontal disease, these drugs have received much 
attention. As a group, the NSAIDs have shown considerable promise and have been proven 
effective in topical and peroral formulations in both animals and humans.217, 218, 230, 231 For 
example in the beagle dog, Paquette and co-workers demonstrated that topical administration 
of 0.03% and 0.3% S-ketoprofen gels significantly decreased the rate of alveolar bone loss 
and gingival index scores over a 60-day period. Similarly, in a 6-month study involving 
adjunctive NSAID treatment in chronic periodontitis patients, Jeffcoat and colleagues 
reported a reduction in alveolar bone loss and GCF PGE2 levels in patients using a 0.1% 
ketorolac mouth rinse.217 
The use of systemically administered NSAIDs in the treatment of periodontitis has 
been somewhat limited due to the inability to sustain long-term positive periodontal effects 
following NSAID withdrawal and concerns of tolerability and adverse systemic effects upon 
long-term systemic NSAID administration.216, 232 Therefore, further studies of topical 
formulations and evaluation of emerging NO-NSAIDs, which are hoped to have a more 
favorable side effect profile, should prove beneficial.  
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Triclosan is an antimicrobial that also appears to have the ability to modulate the host 
response. In addition to its antibacterial effects, triclosan has also been shown to decrease 
PGE2, IL-1, and IFN- production in human fibroblast cell cultures.233-236 It is currently 
believed that its effects on prostaglandin production are due to inhibition of prostaglandin E 
synthase production, rather than COX inhibition, the predominant mechanism of the 
NSAIDs.234 Triclosan has been approved by the FDA for use in a dentifrice and has anti-
plaque and anti-gingivitis indications.  
Bisphosphonates are drugs commonly prescribed for the treatment of osteoporosis 
and other metabolic bone disorders. These medications inhibit osteoclast activity through the 
direct induction of osteoclast apoptosis as well as inhibition of farnesyl pyrophosphate, an 
essential enzyme for normal osteoclast function. Although bisphosphonates have shown 
some benefit in the prevention of bone loss associated with periodontitis, they have not been 
found to substantially improve clinical parameters of periodontal disease.231 Furthermore, the 
chronic administration of these drugs for the treatment of periodontal disease raises concerns 
regarding therapeutic benefit versus risk of gastrointestinal irritation/ulceration and 
potentially significant systemic adverse events.   
Due to the close association of IL-1 and TNF- with inflammation and tissue 
destruction, modulation of these cytokines has been an area of interest for the treatment of 
various chronic inflammatory diseases, including periodontitis. In 1998, Assuma and 
colleagues evaluated the use of IL-1 and TNF- antagonists (soluble receptors) in 
experimental periodontitis using Macaca fasicularis monkeys. They reported that these 
cytokine antagonists inhibited progression of the inflammatory front toward the alveolar crest 
and reduced the associated bone loss.43  Further studies by this group have similarly shown 
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positive results and have demonstrated decreased osteoclast recruitment, connective tissue 
attachment loss, and alveolar bone loss following IL-1 and TNF- inhibition ( 6µg/injection 
of each drug three times weekly for 6 weeks).237-239 However, they have also demonstrated 
that these anti-cytokine therapies have negligible effects on gingival inflammation and result 
in delayed wound healing.237-240 Additionally, in phase IV human clinical studies for arthritis 
and Crohn’s indications, these drugs have been associated with a significantly increased risk 
for severe infection; and therefore should be used with caution. 
 Currently, of all the drug classes studied for the treatment of periodontitis via host 
modulatory effects, the anti-collagenolytics/MMP inhibitors have been the only class to have 
a drug approved for this indication. A sub-antimicrobial dose (20mg bid) of doxycycline, a 
member of the tetracycline antibiotics, received regulatory approval in the US in 1998 for the 
adjunctive treatment of chronic periodontitis. Tetracyclines, in addition to their utility in the 
treatment of bacterial infections, have also been shown to inhibit matrix metalloproteinases, 
and nitric oxide production independent of their antibiotic activity.241-243 The adjunctive use 
of sub-antimicrobial dose doxycycline (SDD) has been  demonstrated to significantly reduce 
loss of connective tissue attachment, improve probing pocket depth, decrease alveolar bone 
loss and decrease GCF collagenase levels in patients with chronic periodontitis, while not 
affecting subgingival microbial profiles or antibiotic resistance.244-247 The inhibition of 
MMPs may also account for a portion of the actions of locally delivered tetracycline 
antibiotics as well. Among the currently approved tetracyclines, doxycycline appears to have 
the strongest anti-collagenase activity; however, multiple chemically modified tetracyclines 
are being developed which have even more pronounced effects on MMP inhibition.248 
Additionally, many of these drugs appear to inhibit osteoclast activity, prevent the release of 
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histamine and inflammatory mediators from mast cells, prevent the formation of advanced 
glycation end products (AGEs), and inhibit VEGF. Thus, this area holds much promise for 
the future treatment of periodontal disease.249-251 
Another area that has received considerable interest lately in the treatment of acute 
and chronic inflammatory disorders is the modulation of nitric oxide production via nitric 
oxide synthase inhibitors and free radical scavengers. Agents that work only as antioxidants 
or free radical scavengers have proved to be of little benefit.99 However, the inhibition of 
nitric oxide production has shown considerable promise in preliminary studies.  
 
4.1.1 NITRIC OXIDE SYNTHASE INHIBITION AND PERIODONTAL DISEASE  
Inhibition of nitric oxide synthesis has been proposed to be beneficial in the 
modulation of periodontal disease by preventing the participation of NO and other reactive 
nitrogen species in a variety of pathways which are thought to be deleterious to the host.206 
These pathways include modification of prostaglandin and cytokine production, induction of 
oxidative and peroxidative damage, activation of PARP, and ultimately depletion of cellular 
energy and cell necrosis (Figure 1).206 Although non-selective inhibitors of nitric oxide 
synthase have primarily been studied in inflammatory conditions, inhibitors with iNOS 
specificity have recently been the main focus of investigation due to the documented up-
regulation of iNOS in inflammatory conditions and importance of constitutive forms in 
homeostasis. In addition to inhibiting NO production, some NOS inhibitors, such as the alkyl 
guanidines and aminoguanidine, have also been shown to have alternate mechanisms of 
action.252-254 The alkyl guanidines are a class of selective iNOS inhibitors, including 
mercaptoethylguanidine (MEG) and guanidinoethyldisulfide (GED), that have been 
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demonstrated to be potent inhibitors of iNOS while also simultaneously limiting 
peroxynitrite formation, scavenging available peroxynitrite and NO, and inhibiting 
prostaglandin production via inhibition of COX.252-254 In diabetic models, aminoguanidine 
has been found to prevent the formation of advanced glycated end products (AGEs) in vitro 
and in vivo.193 The formation of AGEs is of interest in periodontology since significant 
elevations in receptors for these products have been found in gingival tissues from diabetic 
patients with periodontitis in comparison to similar population groups who were 
periodontally healthy.255-256 AGEs also elicit a hyperinflammatory response from 
macrophages and delay wound healing.257-259 Therefore, inhibiting the formation of these end 
products should likely be of significant benefit in the prevention of systemic and periodontal 
pathology.   
Although NOS inhibitors have yet to be studied in patients with periodontal disease, 
they have shown promise in animal models upon topical and systemic administration. In the 
modulation of experimental gingivitis in beagle dogs, Paquette and co-workers found that 
twice daily topical application of gels containing selective iNOS inhibitors, MEG (6mg) or 
GED (6mg), significantly reduced the clinical signs of gingival inflammation, including 
gingival index scores and bleeding responses at 8 weeks.260 Other investigators have 
evaluated the effects of NOS inhibition in ligature-induced experimental periodontitis, with 
rather promising results. In 1998, Lohinai demonstrated in a rat model of experimental 
periodontitis that treatment with the iNOS inhibitor MEG, 30mg/kg intraperitoneally four 
times daily, reduced inflammatory extravasation and osteoclastic bone resorption at study 
termination on day 8.206 Subsequently, Di Paola and colleagues reported that treatment with 
aminoguanidine, a semi-selective iNOS inhibitor, (100mg/kg i.p. daily for 8 days) reduced 
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neutrophil infiltration, lipid peroxidation, and presence of nitrotyrosine and poly(ADP-
ribose) polymerase (PARP) in a rat periodontitis model. Additionally, they also found that 
aminoguanidine (AG) treatment resulted in decreased vascular permeability and alveolar 
bone destruction.205 Most recently, Leitao and co-workers demonstrated that daily 
intraperitoneal administration of aminoguanidine and L-arginine methyl ester (L-NAME, a 
non-selective NOS inhibitor), using 5mg/kg and 20mg/kg respectively, significantly reduced 
the extent of the inflammatory cellular infiltrate and maxillary alveolar bone resorption in 
ligature-induced periodontitis in Wistar rats at 11 days. These investigators also evaluated 
several different dosages of the NOS inhibitors and noted that low doses of these NOS 
inhibitors (AG 2.5mg/kg and L-NAME 5 or 10mg/kg) did not significantly reduce bone loss; 
while high doses (AG 100mg/kg and L-NAME 40mg/kg) inhibited neither alveolar bone loss 
nor local inflammatory changes.261 
As demonstrated by the previous studies, NO appears to play an important and rather 
complex role in the immuno-inflammatory process and in the remodeling and maintenance of 
osseous structures. It is therefore logical that modulation of this mediator has potential in the 
treatment of a number of inflammatory conditions including periodontal disease. Conversely, 
with the biphasic pharmacodynamics of NO, insufficient or excessive inhibition of iNOS 
may exacerbate the inflammatory process. 
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5.  ANIMAL MODELS OF PERIODONTAL DISEASE 
In experimental medical studies, the choice of animal model is an important decision 
and is based on a variety of factors such as cost, accessibility, ease of housing and care, 
animal docility, and similarity to humans. The canine has been recognized as a standard 
higher animal model for the study of gingivitis and periodontitis since the 1970s. 
Furthermore, this model has been extensively used in the testing of new interventions and 
chemotherapeutic modalities for the treatment of periodontal disease.218, 262-267 
The similarity of animal models with humans is essential for the determination of 
relevance of findings and extrapolation of results to human subjects. The most commonly 
used animal models for the study of periodontal disease have been the rodent, canine, and 
non-human primate.  
As would be expected, the rodent model, most frequently the rat, is the least 
expensive, and most easily obtained; however, there are significant differences in the 
anatomy and physiology of the dentition and periodontal tissues between rats and humans. 
Naturally occurring periodontal disease in this model is rare, and there are a number of 
differences in the oral flora and elicited immune response.267 
Conversely, primates are the animals which have the greatest degree of genetic and 
phenotypic homology with humans. Their teeth and periodontal structures are very similar to 
those of humans and they have been shown to exhibit naturally occurring periodontitis both 
in captivity and in the wild.267 However, these animals are very difficult to handle, are costly 
to obtain and house, and are rarely necessary for early trials.267 
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In contrast, the canine has proved to be a very useful model in the study of 
periodontal disease. This is due in part to similarities in size and structure of the dentition and 
supporting periodontium to that of humans.267 Furthermore, this model (specifically that of 
the beagle dog) has been shown to have naturally occurring gingivitis and periodontitis in the 
presence of supra and subgingival plaque and calculus accumulations.267 Additionally, their 
immune response has been shown to be similar to that of humans. A study by Lindhe and 
Rylander in 1975 reported clinical and histologic gingival alterations in beagle dogs 
following the cessation of oral hygiene measures.263 The authors found that the initial plaque 
formation and accumulation was accompanied by progressive increases in gingival crevicular 
fluid flow and clinical signs of inflammation which was in accord with the studies of 
experimental gingivitis in humans.263,268 In histologic assessment, they also demonstrated an 
absence of a connective tissue inflammatory cell infiltrate at baseline which gradually 
increased with time and shifted from a PMN dominated lesion to one composed of increasing 
levels of plasma cells and other mononuclear leukocytes.263 Support for the canine as an 
appropriate model for the study of periodontal disease also comes from a recent study by 
Radice and co-workers which  provides further evidence of the similarity of the subgingival 
flora between canines and humans. They found that in naturally occurring periodontitis in the 
canine, the most frequently isolated anaerobes included Bacteroides fragilis, P. gingivalis, 
and P. intermedia.269 Other studies have also shown a strong relationship between the 
presence of T. forsythia and P. gingivalis with attachment loss in ligature-induced 
periodontitis in this animal model.270 Support for the canine model for the study of host 
modulatory therapies comes not only from the histologic and clinical similarities between 
humans and canines in periodontal disease presentation and progression, but also from the 
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noted involvement of key inflammatory mediators in both groups (i.e., PGE2).226 
Furthermore, the periodontal benefit exhibited with of inhibition of these mediators has 
similarly been documented in humans and canines.218, 219, 226 
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6.  STUDY DESCRIPTION 
Due to the documented involvement of inducible nitric oxide synthase in the 
immuno-inflammatory process, its up-regulation in chronic inflammatory conditions, 
including periodontal disease, and the purported benefits of NOS inhibition in animal models 
of periodontal disease, the current study was designed with the objectives of:  1) evaluating 
the feasibility and safety of topical and systemic administration of three novel iNOS 
inhibitors in experimental gingivitis and periodontitis; 2) testing the hypothesis that over-
expression of iNOS is detrimental to the periodontal tissues; and therefore, its inhibition 
should lessen the extent and severity of gingival inflammation in the canine model of 
gingivitis; and conversely 3) testing the alternative hypothesis that iNOS is essential for 
periodontal homeostasis and serves a protective role during this disease process.  
 
6.1  SPECIFIC AIMS: 
 Phase I: Safety/ Feasibility 
1) To assess the safety and feasibility of topical and systemic (peroral and 
subcutaneous) administration of three novel iNOS inhibitors, designated WW-85, 
IMS, and INO-1001, in canine models of experimental gingivitis and periodontitis.   
2) To collect preliminary data on the effects of these drugs on clinical signs of 
inflammation and radiographic progression of alveolar bone loss in experimental 
gingivitis and periodontitis. 
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Phase II:
To specifically evaluate the effects of the selective iNOS inhibitor, INO-
1001, on the modulation of experimental gingivitis in the canine model. 
 
6.2  METHODS: 
 
After obtaining protocol approval by the University of North Carolina Institutional 
Animal Care and Use Committee, the following randomized, placebo controlled study was 
initiated. The investigation was blinded and was conducted in two distinct phases. A total of 
30 female beagle dogs, having received no antimicrobial or anti-inflammatory agents within 
previous 6 months, were included in the study. All animals were approximately 1 year of age 
with permanent dentitions. Upon arrival, animals were inspected by a veterinarian, housed in 
cages, and fed Sensible Choice canned dog food (Royal Canin, Inc., St. Charles, MO, USA) 
and water ad libitum. During pre-treatment scaling/polishing and all subsequent clinical 
examinations, the animals were anesthetized using 0.2 mg/kg acetyl promazine maleate, 15-
17 mg/kg thiopental sodium, and 0.11 mg/kg atropine. Following sedation, all animals were 
monitored for post-operative recovery by the research team.  Daily intraoral inspections were 
performed for evidence of oral mucosal reactions during the treatment period.  In addition, 
animals were weighed bi-weekly to monitor weight gain/loss and to insure adequate feeding. 
Any animal that experienced signs of weight loss or adverse outcome due to study 
procedures was to be examined by the veterinary staff and, if appropriate, withdrawn from 
the study.   
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Phase I : Safety/Feasibility
Phase I of the study (safety and feasibility of topical and systemic iNOS inhibitors) 
involved 12 dogs (3 per treatment arm), and consisted of four segments: 1) pretreatment, 2) 
experimental gingivitis, 3) recovery, and 4) ligature-induced periodontitis. 
Pretreatment: 
During the pretreatment phase all dogs were brought to optimal health with thorough 
mechanical scaling and tooth polishing, followed by daily rigorous tooth brushing.  Tooth 
brushing continued over a 14 day period until all beagles exhibited low inflammation scores 
(i.e., mean gingival index < 0.5).271 
Experimental Gingivitis: 
At the conclusion of the pretreatment period, beagles were randomized via random 
number table to one of four treatment arms: 1) INO-1001 0.1mg/ml gel, 2) IMS 120mg/ml 
gel, 3) WW-85 0.1mg/ml gel, or 4) placebo gel. All gels were formulated by Inotek 
Corporation (Beverly, MA) and were packaged into masked color-coded syringes.  
 During the 8-week period of experimental gingivitis, all oral hygiene measures were 
discontinued and the animals were maintained on a plaque-promoting diet consisting of 
canned dog food and water. Two milliliters (ml) of the randomized study formulations were 
applied to the buccal gingiva twice daily. Upon dosing, each beagle was held and its lips 
reflected while the gel formulation was expressed around the buccal surfaces of all premolar 
teeth. Care was taken not to disrupt any developing plaque deposits during these procedures.  
 Clinical plaque formation and gingival inflammation were assessed at baseline, and at 
weeks 2, 4, 6 and 8 during gel treatments. Clinical measures were recorded at distobuccal, 
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buccal, and mesiobuccal sites for premolar teeth only and included gingival and plaque 
indices.271, 272 Also, the presence (percent) and extent of bleeding (modified sulcular bleeding 
index) to gentle periodontal probing was determined using a manual UNC-15 periodontal 
probe.273, 274 A single masked examiner was pre-calibrated to assure greater than 90% 
absolute intra-examiner reliability, and performed all clinical index evaluations.  
 Animals were weighed bi-weekly throughout the treatment period. At pretreatment 
and week 8, 5.0 ml of blood was collected from each animal and analyzed to ascertain 
electrolyte status, renal and hepatic function, acute myocardial infarction enzymes and 
metabolic bone disease indicators. 
Recovery/ washout: 
 The beagles were allowed to recover from investigational procedures for a minimum 
of 6 weeks prior to initiation of experimental periodontitis.  During this time, all dogs were 
brought back to gingival health by mechanical scaling and daily tooth brushing.  
Ligature-induced periodontitis: 
To induce experimental periodontitis, 4.0 silk ligatures were placed around 
mandibular premolar teeth and oral hygiene measures were ceased.214, 264, 265, 275 Upon 
initiation of the ligature-induced periodontitis phase, beagles were again randomized to one 
of four treatment arms: 1) INO-1001 30 mg/kg peroral (p.o.) once daily 2) IMS 30 mg/kg 
p.o. once daily 3) WW-85 3 mg/kg subcutaneous once daily, and 4) placebo p.o. once daily.   
 Radiographic examinations were conducted at baseline, week 4 and week 8. At the 4-
week exam, ligature retention was checked and any loose or missing ligatures were replaced. 
Using customized occlusal stents, standardized, intraoral, periapical films were obtained at 
each time point. Stents were fabricated with the use of Regisil vinyl polysiloxane impression 
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material (Dentsply Caulk, Milford, DE) and Rinn XCP bite blocks (Dentsply International, 
Elgin, IL).276 The source to object distance was fixed such that effects of magnification could 
be easily calculated. Care was also taken to minimize angulation errors by aligning the area 
of interest/ film perpendicular to the source beam and paralleling the XCP arm with a fixed 
vertical reference. Direct digital radiographs were obtained using a CCD (charge-coupled 
device) and a personal computer. All radiographs were exposed at 60 Kvp and 4 mAmps for 
1 second and analyzed using appropriate software. Following acquisition, digital images 
were processed for enhancement of geometric standardization and contrast correction via 
Ruttimann algorithm: Subtraction radiography was then utilized to assess areas of alveolar 
bone density loss.277, 278 Vertical linear measurements were made adjacent to the tooth roots 
at each interproximal site and mid-furcally. Again, individual body weights were recorded 
biweekly throughout the treatment period, and 5.0 ml of blood was collected  from each 
animal for laboratory assessment at pretreatment and at week 8. 
 
Phase II: Evaluation of INO-1001 in Experimental Gingivitis
For the second phase of the study, the protocol was amended to concentrate on the 
evaluation of topically administered INO-1001 versus placebo in an appropriately powered 
cohort with experimentally induced gingivitis. Using the gingival index (GI) as the primary 
outcome, the sample size was calculated a priori assuming normally distributed means. It 
was determined that a sample size of 9 beagles per treatment group would allow for detection 
of  significant differences coinciding with a 0.18 stardard deviation and a 0.3 difference, at an 
 level of 0.05 and a  level of 0.10. (The standard deviation used was a previously reported 
value for placebo treated canines during an experimental gingivitis study.)279 Since two 
groups were planned for the study, eighteen female beagles (9 per treatment arm) were 
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included. The pre-treatment and experimental gingivitis protocol used in Phase I was also 
followed in Phase II, with the exception of the use of a new, more bio-adherent formulation 
of topical INO-1001 gel. Clinical indices of plaque formation and gingival inflammation 
were assessed at baseline, week 4, and week 8 during experimental gingivitis. Clinical 
measures were recorded at distobuccal, buccal, and mesiobuccal sites for premolar teeth only 
and included gingival and plaque indices.271, 272 
Again, animals were weighed bi-weekly throughout the treatment period. At baseline 
and week 8, 5.0ml of blood was collected from each animal and analyzed to ascertain 
electrolyte status, renal and hepatic function, acute myocardial infarction enzymes and 
metabolic bone disease indicators. 
 
6.3  STATISTICAL ANALYSIS 
 
For all numeric analyses in this study, the dog was considered the primary unit of 
analysis and outcomes were averaged across the animal and time point. Outcome scores for 
each group were represented as a mean ± the standard deviation (sd), and in all instances 
where appropriate, the data were further analyzed for determination of statistical significance 
using SAS/STAT statistical software (SAS Corporation, Cary, NC). 
 Due to the preliminary nature of phase I of the study, and consequent small sample 
size per group, the analysis was limited to descriptive statistics (i.e., means and standard 
deviations).  For phase II results, all differences in mean clinical indices between groups 
were analyzed for significance at the 0.05 level using general linear models (GLM). 
Additionally, GI and MSBI scores were dichotomized to yield severity scores (i.e., 
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percentage of sites scoring a 2 or 3) and were further analyzed for significant intergroup 
differences. 280 
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7.  RESULTS 
 Phase I: 
During the study, adverse events were monitored and no clinically significant 
abnormalities were noted individually or among groups in regard to blood chemistries, 
hematologic profiles, body weights, or oral mucosal ulceration/ pathology (mean weights are 
presented in Figure 2). However, early during phase I experimental periodontitis, all animals 
in the WW-85 treatment group were withdrawn from the study following local abscess 
formation at the subcutaneous injection site (dorsal cervico-thorasic region). Upon 
examination of the WW-85 injectable formulation, no bacterial growth was observed; 
however, contamination with an unidentified solid particulate was noted. Also during this 
phase of treatment, one dog from the placebo group expired while under general anesthesia at 
the week 4 examination. An autopsy was subsequently performed; however, with the 
exception of a possible untoward effect of the general anesthetic, no causative factor could be 
determined and no overt pathology was observed.  
 Phase I mean gingivitis and plaque scores (PI, GI, BOP, MSBI) are summarized in 
Table 1. All groups displayed an increase in mean plaque and gingival indices between the 
baseline and week 4 examinations; these scores were further increased by the week 8 exam, 
confirming the effectiveness of the established methods for induction of experimental 
gingivitis. An unexpected tendency for increased gingival inflammation and sulcular 
ulceration, as evidenced by bleeding scores, was observed in the iNOS inhibitor treated 
groups, and most notably the WW-85 group.  
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Regarding phase I experimental periodontitis, the mean radiographic bone loss 
measurements (displayed in Figure 3) demonstrated increasing bone loss between baseline 
and week 8 for all groups secondary to ligature placement. Similar to our observations in the 
experimental gingivitis phase, animals dosed with iNOS inhibitors appeared to show greater 
periodontal disease progression as compared to placebo-dosed animals. However, these 
results should be interpreted with caution due to loss of one placebo animal prior to study 
completion and decreased ligature retention in the remaining placebo animals. The 
percentages of ligatures retained for IMS, INO-1001, and placebo treated groups respectively 
were 100%, 66%, and 50% at week 4 and 100%, 100%, and 50% at week 8. It therefore can 
be reasoned that any comparisons with this control group would have the potential to be 
considerably biased.  
 
Phase II:
In concordance with phase I, no adverse events or clinically significant abnormalities 
were noted individually or among groups in regard to blood chemistries, hematologic 
profiles, body weights, or oral mucosal ulceration/ pathology. 
 The mean outcomes of phase II experimental gingivitis are presented in Figures 4-7. 
Once again, all groups displayed increases in mean plaque and gingival index scores from 
baseline to week 4; these scores were further increased by week 8. No significant differences 
were noted between groups for any of the clinical outcome measures at the baseline or 4-
week exams. However by week 8, treatment with the iNOS inhibitor, INO-1001, resulted in 
more pronounced gingival inflammation as evidenced by significantly higher mean scores for 
GI, BOP, and MSBI in comparison to placebo (p<0.0001). This enhanced inflammation was 
noted in the absence of any significant differences in mean plaque index scores between 
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groups at week 8. The INO-1001 treated group displayed a mean BOP difference of 34.9% 
when compared to control (49.7% vs. 14.8%); this represented an approximate 236% 
elevation over placebo. Similarly, in regard to the modified sulcular bleeding index, placebo 
treated animals had a 366% lower mean score than those treated with INO-1001 (0.24 vs. 
0.88). The mean GI scores for the INO-1001 and placebo groups were 1.39 and 0.98, 
respectively. Although not as marked as the differences noted in BOP and MSBI, the 
difference in the mean gingival index between groups was found to be significant (0.41, a 
42% increase over placebo). Furthermore, when GI and MSBI scores were dichotomized to 
yield severity scores, significant differences among the groups were once again noted. The 
severity scores for GI, 39.6 vs. 7.7, and MSBI, 38.8 vs. 9.5, in the INO-1001 versus placebo 
groups respectively were found to be over 4-fold higher in the INO-1001 treated group. All 
above mentioned findings at the 8-week time point were found to be significant at the 
p<0.0001 level.   
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8.  DISCUSSION 
 
Over the past decade, many studies have been conducted to elucidate the role of nitric 
oxide in the immuno-inflammatory response and characterize its potential involvement in the 
pathogenesis of periodontal disease. Numerous reports have established the presence of 
inducible nitric oxide synthase in gingival tissues and have demonstrated its subsequent up-
regulation in humans and animals with periodontal disease.104-106, 205, 206, 209, 210 Furthermore, 
the benefits of nitric oxide synthase inhibition in the modulation of the gingival inflammatory 
response and inhibition of alveolar bone loss in animal models have been repeatedly 
documented.205, 206, 260, 261 These findings, however, are in marked contrast to those of the 
present study which demonstrated an enhanced inflammatory response upon inhibition of 
inducible nitric oxide synthase with the agents tested. This observed progression of 
periodontal disease with the intended inhibition of iNOS activity was consistently noted in all 
phases of the investigation (i.e., phase II results were concordant with phase I findings of 
higher gingival inflammation scores and alveolar bone loss means). The results of the current 
study therefore support a possible dual role for iNOS in the periodontal disease process and 
suggest that iNOS may be essential for periodontal homeostasis. 
 In attempting to understand the inconsistencies between the results of the present 
study and those that have previously been published, an appreciation of the presence and 
locations of the nitric oxide synthase isoenzymes within the periodontal tissues is necessary.  
In 1998, Lohinai and co-workers described the localization and potential function of the three 
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NOS enzymes (nNOS, iNOS, eNOS) in the periodontium based upon animal studies.207 This 
classic report provides the framework for the following discussion of NOS enzyme 
localization. It has been demonstrated by several groups that the gingival epithelium 
expresses iNOS with most activity being localized to the basal keratinocytes and 
intraepithelial macrophages.41, 209 Low levels of enzyme expression have even been observed 
in the tissues of periodontally healthy patients, leading to the presumption that iNOS may be 
constitutively expressed or continually induced in the gingival epithelium. This type of 
expression is seen in the epithelium of the nasal mucosa and the paranasal sinuses and is 
thought to be a protective mechanism against persistent microbial challenge.90 Just beneath 
the epithelium exists an extensive vascular plexus in which the endothelial cells display both 
eNOS and iNOS.207 Surrounding this plexus is an intricate network of nNOS containing 
nerve fibers and eNOS and nNOS positive mast cells.281, 282  It has been demonstrated that 
endogenous nitric oxide production and treatment with nitric oxide donors act to stabilize 
mast cells, preventing their degranulation and release of inflammatory mediators.282, 283 It is 
therefore believed that the constitutive NO produced by the adjacent nerve fibers and 
endothelium may act to stabilize the mast cells of the periodontium. Endothelial NOS and 
iNOS are expressed by the gingival and PDL fibroblasts and local phagocytic cells within the 
connective tissue (macrophages and neutrophils express all three of the NOS 
isoenzymes).41,152,170  In the underlying alveolar bone, osteoblasts and osteoclasts possess 
both iNOS and eNOS, while osteocytes express both eNOS and nNOS.284-286 As has been 
demonstrated, there is extensive overlap in the expression of the three NOS isozymes within 
the cells and tissues of the periodontium; therefore, it is possible that alterations in one 
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isozyme (i.e., iNOS) may result in untoward effects due to compensation or dysregulation of 
the others (i.e., eNOS and nNOS). 
 Lohinai and Di Paola have both reported the substantial presence of constitutive NOS 
(cNOS: eNOS and nNOS) expression in the gingival tissues of rats, which was down-
regulated following the up-regulation of iNOS.205, 206 In streptococcal cell wall-induced 
arthritis in rats, McCartney-Francis demonstrated the up-regulation of iNOS, eNOS and 
nNOS protein expression in diseased versus healthy joints.287 The administration of L-NIL (3 
mg/kg i.p. daily), a selective iNOS inhibitor, resulted in decreased mRNA and protein 
expression for iNOS and a slight up-regulation of eNOS mRNA expression. The up-
regulation of cNOS activity in the absence of iNOS was found to result in an increase in the 
inflammatory infiltrate and “extreme tissue destruction including extensive loss of bone and 
cartilage” by day 24.287  This response was markedly worse when compared to diseased joints 
in which iNOS had not been inhibited. Conversely, administration of the non-selective NOS 
inhibitor, L-NMMA (30 mg/kg i.p. daily), significantly decreased inflammatory joint 
pathology.287 Furthermore, a study of orthodontic tooth movement in a rodent model 
demonstrated that non-selective NOS inhibitors significantly delayed tooth movement; 
whereas an iNOS specific inhibitor had no effect, implicating eNOS and nNOS in osseous 
destruction.288 Neutrophils and macrophages with altered expression of iNOS or cNOS have 
been noted to cause both chemotactic defects and overproduction of superoxide which may 
result in increased susceptibility to infection or increased tissue damage.150,170-172,287,299 
Additionally, while abolishing or significantly increasing NO production has been shown to 
inhibit osteoclastic bone resorption, low levels of NO production (which could potentially be 
produced by increased nNOS or eNOS expression in inflammatory lesions) have been shown 
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to act together with PGE2 to enhance bone resorption.156-159  From these reports it can be 
inferred that cNOS expression may be more highly associated with tissue destruction than 
iNOS; and iNOS may actually serve in a protective role. 
 NO acts as a feedback inhibitory signal for its own production.159 Since iNOS 
induction results in greatly elevated NO production for an extended duration, it would be 
reasonable to postulate that its induction could result in deactivation and subsequent down-
regulation of eNOS and nNOS.205 This may actually serve to limit angiogenesis and vascular 
permeability in chronic inflammatory conditions since eNOS has been determined to be the 
isozyme predominantly responsible for the NO-mediated actions of vascular endothelial 
growth factor (VEGF), a potent factor for the induction of angiogenesis and vascular 
permeability.168, 289 VEGF production has been shown to be induced in gingival fibroblasts 
by the periodontal pathogens P. gingivalis and A. actinomycetemcomitans, and has been 
reported to be increased in gingival tissues of periodontal patients and diabetics.290-294 It has 
also been demonstrated that non-selective NOS inhibitors inhibit both VEGF-induced 
vascular permeability and vascular proliferation while the lack of iNOS activity alone does 
not.295-298 
Inducible nitric oxide synthase has also been demonstrated to be important in TLR 
signaling, and iNOS deficiency has been shown to impair clearance of P. gingivalis, decrease 
PMN survival and enhance tissue damage.150, 169, 300 
Therefore, potent selective iNOS inhibition as potentially observed in the present 
experiment may result in enhanced cNOS expression/activity, increased host mediated 
periodontal destruction, impaired host immune response and reduced bacterial clearance. 
This could subsequently enhance the vascularity, vascular permeability and edema in 
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gingival tissues, while also allowing for increased direct and indirect pathogen-mediated 
tissue destruction.   
 Although the proposed mechanisms outlined above may aid in understanding the 
results of the current study, they are unable to adequately resolve the inconsistencies between 
the findings of the current study and those previously reported. These inconsistencies may 
reflect publication bias toward studies demonstrating positive results; however, they may also 
be explained by the use of non-selective or semi-selective NOS inhibitors in previous 
investigations. 205, 206, 261, 301 Thus, inhibition of not only iNOS, but also eNOS and nNOS 
may have been responsible for the observed beneficial effects.205, 206, 261, 301 Additionally, 
studies that used selective iNOS inhibitors may have shown positive effects in the 
modulation of periodontal disease as a result of COX inhibition, peroxynitrite scavenging, or 
incomplete iNOS inhibition.206,260  
 Before drawing conclusions from the presented results, the potential limitations of the 
current study should first be assessed. One aspect of the study design that may be viewed as a 
potential limitation is its relatively short duration of 8 weeks. Other experimental gingivitis 
studies in this model, however, have shown markedly increased measures of gingival 
inflammation by the 8-week time point with only relatively minor changes being noted in 
gingival index measures thereafter.219,266,279 Studies by Howell and Paquette have also 
demonstrated a diminution of benefits derived from host modulatory therapy beyond the 8-
week time point, likely due to the presence of an overwhelming bacterial burden.219, 266 
Therefore, although seemingly short, this study duration was selected due to the pronounced 
gingival inflammatory and host modulatory responses generally noted in this model by   
week 8.   
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Another potential limitation of the present study is that it was designed to evaluate 
clinical rather than biochemical effects of INO-1001 in experimental gingivitis. Because 
histologic or biochemical evaluations of the gingival tissues/GCF were not conducted, the 
mechanism by which INO-1001 exerted its effects in this study cannot definitively be 
proven.  
 Also, in assessing the validity of the study results, an evaluation of the outcomes for 
the placebo group in comparison to other studies is warranted. Although the mean score for 
bleeding on probing in the placebo group at week 8 is lower than that previously reported by 
Paquette and colleagues in 2006 (i.e., BOP~ 15% vs. 32%), the current study was initiated 
with a lower baseline level of gingival inflammation (i.e., GI~ 0.19 vs. 0.3 and BOP~ 3% vs. 
15%); and therefore, this variation is reasonable.260 Also, the mean GI, BOP, and MSBI 
scores reported here for placebo-treated animals at baseline and week 8 are in agreement with 
those of similarly designed studies published by Howell and colleagues.219, 279 
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9.  CONCLUSIONS 
 
In an assessment of safety and toxicity, the results indicate that the selective iNOS 
inhibitors IMS, WW-85, and INO-1001 in topical and peroral forms appear safe and produce 
no mucosal reactions or systemic events in the canine model. 
 Regarding the effects of iNOS inhibitors in the modulation of experimental 
periodontitis, the selected inhibitors tested in this preclinical investigation, IMS 30mg/kg and 
INO-1001 30mg/kg, appeared to increase periodontal disease progression in the beagle dog. 
However, caution should be used in the interpretation of these results as comparisons are 
made to a biased placebo group, secondary to reduced ligature retention and attrition of one 
animal in this group. 
In contrast to the previously reported benefits of NOS inhibitors in decreasing 
gingival inflammation, the present investigation found that selective iNOS inhibition with the 
agent INO-1001 appeared to exacerbate the extent and severity of experimentally induced 
gingivitis in the canine model. These results suggest that iNOS may be essential for 
periodontal homeostasis and may serve a protective role during this disease process.  
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Figure 1
Proposed mechanism by which iNOS inhibitors prevent cellular 
injury and tissue destruction 
 
Pro-inflammatory Stimuli
(e.g., Periodontal Pathogens, LPS Endotoxin)
Inflammatory Cell Dysfunction
Tissue Destruction
(e.g., Periodontal Disease Progression)
NF-B
Activation
PMN Infiltration 
And Activation
Inducible Nitric Oxide 
Synthase (iNOS)
O2-
ONOO-
Tyrosine
Nitration
Oxidative and 
Peroxidative Injury
Inhibition of 
Mitochondrial 
Respiration and 
Depletion
Of Cellular Energy
COX-2
O2-
H2O2
OH•
DNA Single
Strand Breaks
PARP, Depletion of NAD
Inhibition of ATP-Generating Pathways
NO•
Cytokines 
Chemokines
iNOS 
inhibitor
iNOS 
inhibitor
Adapted from Lohinai et al 1998 &  
 Rosenberg 2002 
 
59
Table 1 
Phase I - Experimental Gingivitis:
Mean Outcomes by Treatment Group 
(Mean +/- Standard Deviation)
0.07 +/- .244.8% +/- 1.90.14 +/- .250.17 +/- .29BaselineINO-1001 
0.22 +/- .3811.1% +/- 5.60.98 +/- .212.17 +/- .29Week 4n=3
0.54 +/- .5727.0% +/- 4.51.17 +/- .262.53 +/- .44Week 8
Modified Sulcular 
Bleeding Index
% Bleeding on 
ProbingGingival IndexPlaque Index
Treatment Groups  
(n= #animals/ group)
0.79 +/- .6638.9% +/- 2.31.26 +/- .292.58 +/- .44Week 8
0.61 +/- .5027.8% +/- 5.91.09 +/- .322.17 +/- .33Week 4n=3
0.12 +/- .1911.1%+/- 2.30.13 +/- .220.10 +/- .24BaselineWW-85 
0.51 +/- .5024.6% +/- 13.81.03 +/- .242.60 +/- .33Week 8
0.35 +/- .5416.7% +/- 7.80.99 +/- .252.25 +/- .29Week 4n=3
0.17 +/- .3011.1% +/- 4.10.18 +/- .290.21 +/- .32BaselineIMS 
0.36 +/- .4617.9% +/- 7.91.06 +/- .242.25 +/- .43Week 8
0.54 +/- .5627.6% +/- 4.90.88 +/- .321.81 +/- .35Week 4n=3
0.05 +/- .164.1% +/- 1.10.13 +/- .230.04 +/- .13BaselinePlacebo 
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Figures 2a & 2b
Figure 2a Mean Pre & Post Treatment  Weights                                                                                                                    
Stratified by Treatment Group 
Phase I: Experimental Gingivitis 
 
Figure 2b Mean Pre & Post Treatment Weights 
Stratified by Treatment Group 
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Figure 3
Phase I - Experimental Periodontitis Outcomes: 
Mean Radiographic Bone Loss (in millimeters) Stratified by 
Treatment Group and Time Point 
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Figure 4
Phase II - Experimental Gingivitis Outcomes: 
Mean Plaque Index (PI) Scores Stratified by Treatment 
Group and Time Point 
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Figure 5
Phase II - Experimental Gingivitis Outcomes: 
 Mean Gingival Index (GI) Scores Stratified by Treatment 
 Group and Time Point 
 
* p< 0.0001 using General Linear Models (GLM) 
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Figure 6
Phase II - Experimental Gingivitis Outcomes: 
 Mean Bleeding on Probing Scores Stratified by Treatment 
 Group and Time Point 
 
Figure 7
* p< 0.0001 using General Linear Models (GLM) 
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Figure 7
Phase II - Experimental Gingivitis Outcomes: 
 Mean Modified Sulcular Bleeding Scores Stratified    
 Group and Time Point 
 
0.00
0.20
0.40
0.60
0.80
1.00
1.20
B aseline Week 4 Week 8
A
ve
ra
ge
M
SB
IS
co
re
Placeb o IN O- 10 0 1
*
* p< 0.0001 using General Linear Models (GLM) 
M
ea
n
M
SB
IS
co
re
s
66
REFERENCES 
1. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol 1996;1(1):821-878. 
2. Kinane DF, Riggio MP, Walker KF, MacKenzie D, Shearer B. Bacteraemia following 
periodontal procedures. J Clin Periodontol 2005;32(7):708-713. 
3. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth 
brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol 
2006;33(6):401-407. 
4. Geerts SO, Nys M, De MP, et al. Systemic release of endotoxins induced by gentle 
mastication: association with periodontitis severity. J Periodontol 2002;73(1):73-78. 
5. Beck JD, Offenbacher S. Systemic effects of periodontitis: epidemiology of periodontal 
disease and cardiovascular disease. J Periodontol 2005;76(11 Suppl):2089-2100. 
6. Mattila KJ, Nieminen MS, Valtonen VV, et al. Association between dental health and 
acute myocardial infarction. BMJ 1989;298(6676):779-781. 
7. Pussinen PJ, Alfthan G, Rissanen H, Reunanen A, Asikainen S, Knekt P. Antibodies to 
periodontal pathogens and stroke risk. Stroke 2004;35(9):2020-2023. 
8. Dorfer CE, Becher H, Ziegler CM, et al. The association of gingivitis and periodontitis 
with ischemic stroke. J Clin Periodontol 2004;31(5):396-401. 
9. Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. 
Ann Periodontol 1998;3(1):51-61. 
10. Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. A proposed model linking 
inflammation to obesity, diabetes, and periodontal infections. J Periodontol 2005;76(11 
Suppl):2075-2084. 
11. Bobetsis YA, Barros SP, Offenbacher S. Exploring the relationship between periodontal 
disease and pregnancy complications. J Am Dent Assoc 2006;137 Suppl:7S-13S. 
12. Lopez NJ, Smith PC, Gutierrez J. Periodontal therapy may reduce the risk of preterm low 
birth weight in women with periodontal disease: a randomized controlled trial. J Periodontol 
2002;73(8):911-924. 
13. Offenbacher S, Katz V, Fertik G, et al. Periodontal infection as a possible risk factor for 
preterm low birth weight. J Periodontol 1996;67(10 Suppl):1103-1113. 
14. Michaud DS, Joshipura K, Giovannucci E, Fuchs CS. A prospective study of periodontal 
disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst 
2007;99(2):171-175. 
67
15. Haffajee AD, Teles RP, Socransky SS. The effect of periodontal therapy on the 
composition of the subgingival microbiota. Periodontology 2000 2006;42:219-258. 
16. Carranza F, Shklar G. History of Periodontology. 2003;:200. 
17. Listgarten MA. Structure of the microbial flora associated with periodontal health and 
disease in man. A light and electron microscopic study. J Periodontol 1976;47(1):1-18. 
18. Theilade E, Wright WH, Jensen SB, Loe H. Experimental gingivitis in man. II. A 
longitudinal clinical and bacteriological investigation. J Periodontal Res 1966;1:1-13. 
19. Newman MG, Socransky SS. Predominant cultivable microbiota in periodontosis. J
Periodontal Res 1977;12(2):120-128. 
20. Newman MG, Socransky SS, Savitt ED, Propas DA, Crawford A. Studies of the 
microbiology of periodontosis. J Periodontol 1976;47(7):373-379. 
21. Geesey GG, Richardson WT, Yeomans HG, Irvin RT, Costerton JW. Microscopic 
examination of natural sessile bacterial populations from an alpine stream. Can J Microbiol 
1977;23(12):1733-1736. 
22. Costerton JW, Geesey GG, Cheng KJ. How bacteria stick. Sci Am 1978;238(1):86-95. 
23. McCowan RP, Cheng KJ, Bailey CB, Costerton JW. Adhesion of bacteria to epithelial 
cell surfaces within the reticulo-rumen of cattle. Appl Environ Microbiol 1978;35(1):149-
155. 
24. Kolenbrander PE, Palmer RJ,Jr, Rickard AH, Jakubovics NS, Chalmers NI, Diaz PI. 
Bacterial interactions and successions during plaque development. Periodontology 2000 
2006;42:47-79. 
25. Socransky SS, Haffajee AD. Periodontal microbial ecology. Periodontology 2000 
2005;38:135-187. 
26. Noiri Y, Li L, Ebisu S. The localization of periodontal-disease-associated bacteria in 
human periodontal pockets. J Dent Res 2001;80(10):1930-1934. 
27. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL,Jr. Microbial complexes in 
subgingival plaque. J Clin Periodontol 1998;25(2):134-144. 
28. Noiri Y, Ebisu S. Identification of periodontal disease-associated bacteria in the "plaque-
free zone". J Periodontol 2000;71(8):1319-1326. 
29. Anonymous Consensus report. Periodontal diseases: pathogenesis and microbial factors. 
Ann Periodontol 1996;1(1):926-932. 
68
30. Madianos PN, Bobetsis YA, Kinane DF. Generation of inflammatory stimuli: how 
bacteria set up inflammatory responses in the gingiva. J Clin Periodontol 2005;32 Suppl 
6:57-71. 
31. Paster BJ, Olsen I, Aas JA, Dewhirst FE. The breadth of bacterial diversity in the human 
periodontal pocket and other oral sites. Periodontol 2000 2006;42:80-87. 
32. Medzhitov R, Preston-Hurlburt P, Janeway CA,Jr. A human homologue of the 
Drosophila Toll protein signals activation of adaptive immunity. Nature 
1997;388(6640):394-397. 
33. Kufer TA, Fritz JH, Philpott DJ. NACHT-LRR proteins (NLRs) in bacterial infection and 
immunity. Trends Microbiol 2005;13(8):381-388. 
34. Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique functions of the 
DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 
2005;175(5):2851-2858. 
35. Werts C, Girardin SE, Philpott DJ. TIR, CARD and PYRIN: three domains for an 
antimicrobial triad. Cell Death Differ 2006;13(5):798-815. 
36. Lamster IB, Novak MJ. Host mediators in gingival crevicular fluid: implications for the 
pathogenesis of periodontal disease. Crit Rev Oral Biol Med 1992;3(1-2):31-60. 
37. Lindhe J, Karring T, Lang N. Clinical Periodontology and Implant Dentistry.2003; 1044. 
38. Rose L, Mealey B, Genco R, Cohen D. Periodontics: Medicine, Surgery, and Implants. 
2004;990. 
39. Madianos PN, Bobetsis YA, Kinane DF. Generation of inflammatory stimuli: how 
bacteria set up inflammatory responses in the gingiva. J Clin Periodontol 2005;32 Suppl 
6:57-71. 
40. Dixon DR, Bainbridge BW, Darveau RP. Modulation of the innate immune response 
within the periodontium. Periodontol 2000 2004;35:53-74. 
41. Kendall HK, Haase HR, Li H, Xiao Y, Bartold PM. Nitric oxide synthase type-II is 
synthesized by human gingival tissue and cultured human gingival fibroblasts. J Periodontal 
Res 2000;35(4):194-200. 
42. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev 
Oral Biol Med 1998;9(3):248-266. 
43. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit 
the inflammatory response and bone loss in experimental periodontitis. J Immunol 
1998;160(1):403-409. 
69
44. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. A summary 
of current work. Lab Invest 1976;34(3):235-249. 
45. Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of 
chemokines and regulation of inflammation. Am J Pathol 1997;151(2):317-322. 
46. Park HJ, Park OJ, Shin J. Receptor activator of NF-kappaB ligand enhances the activity 
of macrophages as antigen-presenting cells. Exp Mol Med 2005;37(6):524-532. 
47. Nagasawa T, Kiji M, Yashiro R, et al. Roles of receptor activator of nuclear factor-
kappaB ligand (RANKL) and osteoprotegerin in periodontal health and disease. Periodontol 
2000 2007;43:65-84. 
48. Belibasakis GN, Johansson A, Wang Y, Chen C, Kalfas S, Lerner UH. The cytolethal 
distending toxin induces receptor activator of NF-kappaB ligand expression in human 
gingival fibroblasts and periodontal ligament cells. Infect Immun 2005;73(1):342-351. 
49. Tiranathanagul S, Yongchaitrakul T, Pattamapun K, Pavasant P. Actinobacillus 
actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and 
increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal 
ligament cells. J Periodontol 2004;75(12):1647-1654. 
50. Horton JE, Raisz LG, Simmons HA, Oppenheim JJ, Mergenhagen SE. Bone resorbing 
activity in supernatant fluid from cultured human peripheral blood leukocytes. Science 
1972;177(51):793-795. 
51. Goldhaber P, Rabadjija L, Beyer WR, Kornhauser A. Bone resorption in tissue culture 
and its relevance to periodontal disease. J Am Dent Assoc 1973;87(5):1027-1033. 
52. Stashenko P, Jandinski JJ, Fujiyoshi P, Rynar J, Socransky SS. Tissue levels of bone 
resorptive cytokines in periodontal disease. J Periodontol 1991;62(8):504-509. 
53. Heasman PA, Collins JG, Offenbacher S. Changes in crevicular fluid levels of 
interleukin-1 beta, leukotriene B4, prostaglandin E2, thromboxane B2 and tumour necrosis 
factor alpha in experimental gingivitis in humans. J Periodontal Res 1993;28(4):241-247. 
54. Stashenko P, Dewhirst FE, Peros WJ, Kent RL, Ago JM. Synergistic interactions 
between interleukin 1, tumor necrosis factor, and lymphotoxin in bone resorption. J Immunol 
1987;138(5):1464-1468. 
55. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling 
molecules regulating neutrophil function. Free Radic Biol Med 2007;42(2):153-164. 
56. Assreuy J, Cunha FQ, Epperlein M, et al. Production of nitric oxide and superoxide by 
activated macrophages and killing of Leishmania major. Eur J Immunol 1994;24(3):672-676. 
57. Fernandes PD, Assreuy J. Role of nitric oxide and superoxide in Giardia lamblia killing. 
Braz J Med Biol Res 1997;30(1):93-99. 
70
58. Tohyama M, Kawakami K, Futenma M, Saito A. Enhancing effect of oxygen radical 
scavengers on murine macrophage anticryptococcal activity through production of nitric 
oxide. Clin Exp Immunol 1996;103(3):436-441. 
59. Kantarci A, Oyaizu K, Van Dyke TE. Neutrophil-mediated tissue injury in periodontal 
disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 
2003;74(1):66-75. 
60. Hart TC, Shapira L, Van Dyke TE. Neutrophil defects as risk factors for periodontal 
diseases. J Periodontol 1994;65(5 Suppl):521-529. 
61. Agarwal S, Suzuki JB, Riccelli AE. Role of cytokines in the modulation of neutrophil 
chemotaxis in localized juvenile periodontitis. J Periodontal Res 1994;29(2):127-137. 
62. Genco RJ, Van Dyke TE, Park B, Ciminelli M, Horoszewicz H. Neutrophil chemotaxis 
impairment in juvenile periodontitis: evaluation of specificity, adherence, deformability, and 
serum factors. J Reticuloendothel Soc 1980;28(Suppl):81s-91s. 
63. Van Dyke TE, Zinney W, Winkel K, Taufiq A, Offenbacher S, Arnold RR. Neutrophil 
function in localized juvenile periodontitis. Phagocytosis, superoxide production and specific 
granule release. J Periodontol 1986;57(11):703-708. 
64. Van Dyke TE, Horoszewicz HU, Genco RJ. The polymorphonuclear leukocyte (PMNL) 
locomotor defect in juvenile periodontitis. Study of random migration, chemokinesis and 
chemotaxis. J Periodontol 1982;53(11):682-687. 
65. Shibata K, Warbington ML, Gordon BJ, Kurihara H, Van Dyke TE. Nitric oxide synthase 
activity in neutrophils from patients with localized aggressive periodontitis. J Periodontol 
2001;72(8):1052-1058. 
66. Azuma M. Fundamental mechanisms of host immune responses to infection. J
Periodontal Res 2006;41(5):361-373. 
67. Lu HK, Chen YL, Chang HC, Li CL, Kuo MY. Identification of the 
osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival 
crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 
2006;41(4):354-360. 
68. Vernal R, Dutzan N, Hernandez M, et al. High expression levels of receptor activator of 
nuclear factor-kappa B ligand associated with human chronic periodontitis are mainly 
secreted by CD4+ T lymphocytes. J Periodontol 2006;77(10):1772-1780. 
69. Matsuki Y, Yamamoto T, Hara K. Interleukin-1 mRNA-expressing macrophages in 
human chronically inflamed gingival tissues. Am J Pathol 1991;138(6):1299-1305. 
70. Matsuki Y, Yamamoto T, Hara K. Detection of inflammatory cytokine messenger RNA 
(mRNA)-expressing cells in human inflamed gingiva by combined in situ hybridization and 
immunohistochemistry. Immunology 1992;76(1):42-47. 
71
71. Boyle JJ. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of 
plaque rupture. Curr Vasc Pharmacol 2005;3(1):63-68. 
72. Naguib G, Al-Mashat H, Desta T, Graves DT. Diabetes prolongs the inflammatory 
response to a bacterial stimulus through cytokine dysregulation. J Invest Dermatol 
2004;123(1):87-92. 
73. Salvi GE, Collins JG, Yalda B, Arnold RR, Lang NP, Offenbacher S. Monocytic TNF 
alpha secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol 
1997;24(1):8-16. 
74. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor 
and its ligand enhance T-cell growth and dendritic-cell function. Nature 
1997;390(6656):175-179. 
75. Liljenberg B, Lindhe J. Juvenile periodontitis. Some microbiological, histopathological 
and clinical characteristics. J Clin Periodontol 1980;7(1):48-61. 
76. Lindhe J, Liljenberg B, Listgarten M. Some microbiological and histopathological 
features of periodontal disease in man. J Periodontol 1980;51(5):264-269. 
77. Mackler BF, Frostad KB, Robertson PB, Levy BM. Immunoglobulin bearing 
lymphocytes and plasma cells in human periodontal disease. J Periodontal Res 
1977;12(1):37-45. 
78. Kawai T, Matsuyama T, Hosokawa Y, et al. B and T lymphocytes are the primary 
sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 
2006;169(3):987-998. 
79. Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and 
function of genes encoding cholinergic components in murine immune cells. Life Sci 2007;
80. Skok MV, Grailhe R, Agenes F, Changeux JP. The role of nicotinic receptors in B-
lymphocyte development and activation. Life Sci 2007;
81. Bascones A, Noronha S, Gomez M, Mota P, Gonzalez Moles MA, Dorrego MV. Tissue 
destruction in periodontitis: bacteria or cytokines fault? Quintessence Int 2005;36(4):299-
306. 
82. Dewhirst FE, Stashenko PP, Mole JE, Tsurumachi T. Purification and partial sequence of 
human osteoclast-activating factor: identity with interleukin 1 beta. J Immunol 
1985;135(4):2562-2568. 
83. van der Pluijm G, Most W, van der Wee-Pals L, de Groot H, Papapoulos S, Lowik C. 
Two distinct effects of recombinant human tumor necrosis factor-alpha on osteoclast 
development and subsequent resorption of mineralized matrix. Endocrinology 
1991;129(3):1596-1604. 
72
84. Birkedal-Hansen H. Role of cytokines and inflammatory mediators in tissue destruction. 
J Periodontal Res 1993;28(6 Pt 2):500-510. 
85. Yamazaki K, Nakajima T, Gemmell E, Polak B, Seymour GJ, Hara K. IL-4- and IL-6-
producing cells in human periodontal disease tissue. J Oral Pathol Med 1994;23(8):347-353. 
86. Geivelis M, Turner DW, Pederson ED, Lamberts BL. Measurements of interleukin-6 in 
gingival crevicular fluid from adults with destructive periodontal disease. J Periodontol 
1993;64(10):980-983. 
87. Van Dyke TE, Lester MA, Shapira L. The role of the host response in periodontal disease 
progression: implications for future treatment strategies. J Periodontol 1993;64(8 
Suppl):792-806. 
88. Elias JA, Gustilo K, Baeder W, Freundlich B. Synergistic stimulation of fibroblast 
prostaglandin production by recombinant interleukin 1 and tumor necrosis factor. J Immunol 
1987;138(11):3812-3816. 
89. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone 
resorption and inhibition of bone formation in vitro by human tumour necrosis factors. 
Nature 1986;319(6053):516-518. 
90. Kendall HK, Marshall RI, Bartold PM. Nitric oxide and tissue destruction. Oral Dis 
2001;7(1):2-10. 
91. Kantarci A, Hasturk H, Van Dyke TE. Host-mediated resolution of inflammation in 
periodontal diseases. Periodontol 2000 2006;40:144-163. 
92. Offenbacher S, Odle BM, Van Dyke TE. The use of crevicular fluid prostaglandin E2 
levels as a predictor of periodontal attachment loss. J Periodontal Res 1986;21(2):101-112. 
93. Dietrich JW, Goodson JM, Raisz LG. Stimulation of bone resorption by various 
prostaglandins in organ culture. Prostaglandins 1975;10(2):231-240. 
94. Klein DC, Raisz LG. Prostaglandins: stimulation of bone resorption in tissue culture. 
Endocrinology 1970;86(6):1436-1440. 
95. Meikle MC, Hembry RM, Holley J, Horton C, McFarlane CG, Reynolds JJ. 
Immunolocalization of matrix metalloproteinases and TIMP-1 (tissue inhibitor of 
metalloproteinases) in human gingival tissues from periodontitis patients. J Periodontal Res 
1994;29(2):118-126. 
96. Larivee J, Sodek J, Ferrier JM. Collagenase and collagenase inhibitor activities in 
crevicular fluid of patients receiving treatment for localized juvenile periodontitis. J
Periodontal Res 1986;21(6):702-715. 
73
97. Chen HY, Cox SW, Eley BM, Mantyla P, Ronka H, Sorsa T. Matrix metalloproteinase-8 
levels and elastase activities in gingival crevicular fluid from chronic adult periodontitis 
patients. J Clin Periodontol 2000;27(5):366-369. 
98. Domeij H, Yucel-Lindberg T, Modeer T. Signal pathways involved in the production of 
MMP-1 and MMP-3 in human gingival fibroblasts. Eur J Oral Sci 2002;110(4):302-306. 
99. Chapple IL, Matthews JB. The role of reactive oxygen and antioxidant species in 
periodontal tissue destruction. Periodontol 2000 2007;43:161-233. 
100. Bruckdorfer R. The basics about nitric oxide. Mol Aspects Med 2005;26(1-2):3-31. 
101. Wheeler MA, Smith SD, Garcia-Cardena G, Nathan CF, Weiss RM, Sessa WC. 
Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 
1997;99(1):110-116. 
102. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and 
immune regulation. J Physiol Pharmacol 2003;54(4):469-487. 
103. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. 
Physiol Rev 2007;87(1):315-424. 
104. Hirose M, Ishihara K, Saito A, Nakagawa T, Yamada S, Okuda K. Expression of 
cytokines and inducible nitric oxide synthase in inflamed gingival tissue. J Periodontol 
2001;72(5):590-597. 
105. Matejka M, Partyka L, Ulm C, Solar P, Sinzinger H. Nitric oxide synthesis is increased 
in periodontal disease. J Periodontal Res 1998;33(8):517-518. 
106. Lappin DF, Kjeldsen M, Sander L, Kinane DF. Inducible nitric oxide synthase 
expression in periodontitis. J Periodontal Res 2000;35(6):369-373. 
107. Goodson JM, Dewhirst FE, Brunetti A. Prostaglandin E2 levels and human periodontal 
disease. Prostaglandins 1974;6(1):81-85. 
108. Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a 
determinant of periodontal disease expression. J Periodontol 1993;64(5 Suppl):432-444. 
109. Fredriksson M, Gustafsson A, Asman B, Bergstrom K. Hyper-reactive peripheral 
neutrophils in adult periodontitis: generation of chemiluminescence and intracellular 
hydrogen peroxide after in vitro priming and FcgammaR-stimulation. J Clin Periodontol 
1998;25(5):394-398. 
110. Fredriksson MI, Gustafsson AK, Bergstrom KG, Asman BE. Constitutionally 
hyperreactive neutrophils in periodontitis. J Periodontol 2003;74(2):219-224. 
111. Roberts FA, McCaffery KA, Michalek SM. Profile of cytokine mRNA expression in 
chronic adult periodontitis. J Dent Res 1997;76(12):1833-1839. 
74
112. Sengupta S, Fine J, Wu-Wang CY, et al. The relationship of prostaglandins to cAMP, 
IgG, IgM and alpha-2-macroglobulin in gingival crevicular fluid in chronic adult 
periodontitis. Arch Oral Biol 1990;35(8):593-596. 
113. Jandinski JJ, Stashenko P, Feder LS, et al. Localization of interleukin-1 beta in human 
periodontal tissue. J Periodontol 1991;62(1):36-43. 
114. Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin-1beta, interleukin-12 and 
interleukin-18 levels in gingival fluid and serum of patients with gingivitis and periodontitis. 
Oral Microbiol Immunol 2006;21(4):256-260. 
115. Reinhardt RA, Masada MP, Johnson GK, DuBois LM, Seymour GJ, Allison AC. IL-1 
in gingival crevicular fluid following closed root planing and papillary flap debridement. J
Clin Periodontol 1993;20(7):514-519. 
116. Rawlinson A, Dalati MH, Rahman S, Walsh TF, Fairclough AL. Interleukin-1 and IL-1 
receptor antagonist in gingival crevicular fluid. J Clin Periodontol 2000;27(10):738-743. 
117. Ishihara Y, Nishihara T, Kuroyanagi T, et al. Gingival crevicular interleukin-1 and 
interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. J
Periodontal Res 1997;32(6):524-529. 
118. Figueredo CM, Ribeiro MS, Fischer RG, Gustafsson A. Increased interleukin-1beta 
concentration in gingival crevicular fluid as a characteristic of periodontitis. J Periodontol 
1999;70(12):1457-1463. 
119. Smith MA, Braswell LD, Collins JG, et al. Changes in inflammatory mediators in 
experimental periodontitis in the rhesus monkey. Infect Immun 1993;61(4):1453-1459. 
120. Dongari-Bagtzoglou AI, Ebersole JL. Increased presence of interleukin-6 (IL-6) and IL-
8 secreting fibroblast subpopulations in adult periodontitis. J Periodontol 1998;69(8):899-
910. 
121. Hou LT, Liu CM, Rossomando EF. Crevicular interleukin-1 beta in moderate and 
severe periodontitis patients and the effect of phase I periodontal treatment. J Clin 
Periodontol 1995;22(2):162-167. 
122. Chiueh CC. Neuroprotective properties of nitric oxide. Ann N Y Acad Sci 1999;890:301-
311. 
123. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived 
relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci 
U S A 1987;84(24):9265-9269. 
124. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological 
activity of endothelium-derived relaxing factor. Nature 1987;327(6122):524-526. 
75
125. Moncada S, Higgs EA. Endogenous nitric oxide: physiology, pathology and clinical 
relevance. Eur J Clin Invest 1991;21(4):361-374. 
126. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and 
inhibition. Biochem J 2001;357(Pt 3):593-615. 
127. Szabo C, O'Connor M, Salzman AL. Endogenously produced peroxynitrite induces the 
oxidation of mitochondrial and nuclear proteins in immunostimulated macrophages. FEBS 
Lett 1997;409(2):147-150. 
128. Lacza Z, Pankotai E, Csordas A, et al. Mitochondrial NO and reactive nitrogen species 
production: does mtNOS exist? Nitric Oxide 2006;14(2):162-168. 
129. Ghafourifar P, Sen CK. Mitochondrial nitric oxide synthase. Front Biosci 
2007;12:1072-1078. 
130. Naseem KM. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 
2005;26(1-2):33-65. 
131. Isenberg JS, Ridnour LA, Espey MG, Wink DA, Roberts DD. Nitric oxide in wound-
healing. Microsurgery 2005;25(5):442-451. 
132. Luo JD, Chen AF. Nitric oxide: a newly discovered function on wound healing. Acta 
Pharmacol Sin 2005;26(3):259-264. 
133. Ugar-Cankal D, Ozmeric N. A multifaceted molecule, nitric oxide in oral and 
periodontal diseases. Clin Chim Acta 2006;366(1-2):90-100. 
134. Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in 
apoptosis. Int Immunopharmacol 2001;1(8):1421-1441. 
135. Moncada S, Erusalimsky JD. Does nitric oxide modulate mitochondrial energy 
generation and apoptosis? Nat Rev Mol Cell Biol 2002;3(3):214-220. 
136. Singh VK, Mehrotra S, Narayan P, Pandey CM, Agarwal SS. Modulation of 
autoimmune diseases by nitric oxide. Immunol Res 2000;22(1):1-19. 
137. Suschek CV, Schnorr O, Kolb-Bachofen V. The role of iNOS in chronic inflammatory 
processes in vivo: is it damage-promoting, protective, or active at all? Curr Mol Med 
2004;4(7):763-775. 
138. Pannu R, Singh I. Pharmacological strategies for the regulation of inducible nitric oxide 
synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int 
2006;49(2):170-182. 
139. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and 
antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 
2007;39(1):44-84. 
76
140. Szabo C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett 2003;140-
141:105-112. 
141. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. 
Pharmacol Rev 2002;54(3):375-429. 
142. Lohinai Z, Mabley JG, Feher E, Marton A, Komjati K, Szabo C. Role of the activation 
of the nuclear enzyme poly(ADP-ribose) polymerase in the pathogenesis of periodontitis. J
Dent Res 2003;82(12):987-992. 
143. Pacher P, Obrosova IG, Mabley JG, Szabo C. Role of nitrosative stress and 
peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical 
strategies. Curr Med Chem 2005;12(3):267-275. 
144. Eissa NT, Strauss AJ, Haggerty CM, Choo EK, Chu SC, Moss J. Alternative splicing of 
human inducible nitric-oxide synthase mRNA. tissue-specific regulation and induction by 
cytokines. J Biol Chem 1996;271(43):27184-27187. 
145. Lorenz M, Hewing B, Hui J, et al. Alternative splicing in intron 13 of the human eNOS 
gene: a potential mechanism for regulating eNOS activity. FASEB J 2007;
146. Chan Y, Fish JE, D'Abreo C, et al. The cell-specific expression of endothelial nitric-
oxide synthase: a role for DNA methylation. J Biol Chem 2004;279(33):35087-35100. 
147. Armour KE, Armour KJ, Gallagher ME, et al. Defective bone formation and anabolic 
response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide 
synthase. Endocrinology 2001;142(2):760-766. 
148. Armour KJ, Armour KE, van't Hof RJ, et al. Activation of the inducible nitric oxide 
synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone 
formation and causing osteoblast apoptosis. Arthritis Rheum 2001;44(12):2790-2796. 
149. Aguirre J, Buttery L, O'Shaughnessy M, et al. Endothelial nitric oxide synthase gene-
deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone 
volume, and defects in osteoblast maturation and activity. Am J Pathol 2001;158(1):247-257. 
150. Gyurko R, Boustany G, Huang PL, et al. Mice lacking inducible nitric oxide synthase 
demonstrate impaired killing of Porphyromonas gingivalis. Infect Immun 2003;71(9):4917-
4924. 
151. Ralston SH, Ho LP, Helfrich MH, Grabowski PS, Johnston PW, Benjamin N. Nitric 
oxide: a cytokine-induced regulator of bone resorption. J Bone Miner Res 1995;10(7):1040-
1049. 
152. Brandi ML, Hukkanen M, Umeda T, et al. Bidirectional regulation of osteoclast 
function by nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 1995;92(7):2954-2958. 
77
153. da Rocha FA, de Brum-Fernandes AJ. Evidence that peroxynitrite affects human 
osteoblast proliferation and differentiation. J Bone Miner Res 2002;17(3):434-442. 
154. Damoulis PD, Hauschka PV. Nitric oxide acts in conjunction with proinflammatory 
cytokines to promote cell death in osteoblasts. J Bone Miner Res 1997;12(3):412-422. 
155. Hauschka PV, Damoulis PD. Functions of nitric oxide in bone. Biochem Soc Trans 
1998;26(1):39-44. 
156. Zheng H, Yu X, Collin-Osdoby P, Osdoby P. RANKL stimulates inducible nitric-oxide 
synthase expression and nitric oxide production in developing osteoclasts. An autocrine 
negative feedback mechanism triggered by RANKL-induced interferon-beta via NF-kappaB 
that restrains osteoclastogenesis and bone resorption. J Biol Chem 2006;281(23):15809-
15820. 
157. Holliday LS, Dean AD, Lin RH, Greenwald JE, Gluck SL. Low NO concentrations 
inhibit osteoclast formation in mouse marrow cultures by cGMP-dependent mechanism. Am 
J Physiol 1997;272(3 Pt 2):F283-91. 
158. MacIntyre I, Zaidi M, Alam AS, et al. Osteoclastic inhibition: an action of nitric oxide 
not mediated by cyclic GMP. Proc Natl Acad Sci U S A 1991;88(7):2936-2940. 
159. Ralston SH, Grabowski PS. Mechanisms of cytokine induced bone resorption: role of 
nitric oxide, cyclic guanosine monophosphate, and prostaglandins. Bone 1996;19(1):29-33. 
160. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of 
arterial smooth muscle by acetylcholine. Nature 1980;288(5789):373-376. 
161. Han G, Ma H, Chintala R, et al. Non-genomic, endothelium-independent effects of 
estrogen on human coronary smooth muscle mediated by Type I (neuronal) NOS and PI3 
kinase/Akt signaling. Am J Physiol Heart Circ Physiol 2007;
162. Casadei B. The emerging role of neuronal nitric oxide synthase in the regulation of 
myocardial function. Exp Physiol 2006;91(6):943-955. 
163. Chiang TM, Woo-Rasberry V, Cole F. Role of platelet endothelial form of nitric oxide 
synthase in collagen-platelet interaction: regulation by phosphorylation. Biochim Biophys 
Acta 2002;1592(2):169-174. 
164. Madajka M, Korda M, White J, Malinski T. Effect of aspirin on constitutive nitric oxide 
synthase and the biovailability of NO. Thromb Res 2003;110(5-6):317-321. 
165. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human 
platelet adhesion to vascular endothelium. Lancet 1987;2(8567):1057-1058. 
166. Le X, Wei D, Huang S, Lancaster JR,Jr, Xie K. Nitric oxide synthase II suppresses the 
growth and metastasis of human cancer regardless of its up-regulation of protumor factors. 
Proc Natl Acad Sci U S A 2005;102(24):8758-8763. 
78
167. Desjardins F, Balligand JL. Nitric oxide-dependent endothelial function and 
cardiovascular disease. Acta Clin Belg 2006;61(6):326-334. 
168. Fukumura D, Gohongi T, Kadambi A, et al. Predominant role of endothelial nitric oxide 
synthase in vascular endothelial growth factor-induced angiogenesis and vascular 
permeability. Proc Natl Acad Sci U S A 2001;98(5):2604-2609. 
169. MacMicking JD, Nathan C, Hom G, et al. Altered responses to bacterial infection and 
endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81(4):641-650. 
170. Shibata K, Warbington ML, Gordon BJ, Kurihara H, Van Dyke TE. Nitric oxide 
synthase activity in neutrophils from patients with localized aggressive periodontitis. J
Periodontol 2001;72(8):1052-1058. 
171. Belenky SN, Robbins RA, Rennard SI, Gossman GL, Nelson KJ, Rubinstein I. 
Inhibitors of nitric oxide synthase attenuate human neutrophil chemotaxis in vitro. J Lab Clin 
Med 1993;122(4):388-394. 
172. Gaspirc B, Masera A, Skaleric U. Immunolocalization of inducible nitric oxide synthase 
in localized juvenile periodontitis patients. Connect Tissue Res 2002;43(2-3):413-418. 
173. Kato C, Mikami M, Suzuki A, Saito K. The reduction of Fusobacterium nucleatum in 
mice is irrelevant to the nitric oxide induced by iNOS. Microbiol Immunol 2003;47(1):27-35. 
174. Brunelli L, Crow JP, Beckman JS. The comparative toxicity of nitric oxide and 
peroxynitrite to Escherichia coli. Arch Biochem Biophys 1995;316(1):327-334. 
175. De Groote MA, Granger D, Xu Y, Campbell G, Prince R, Fang FC. Genetic and redox 
determinants of nitric oxide cytotoxicity in a Salmonella typhimurium model. Proc Natl 
Acad Sci U S A 1995;92(14):6399-6403. 
176. Vazquez-Torres A, Jones-Carson J, Balish E. Peroxynitrite contributes to the 
candidacidal activity of nitric oxide-producing macrophages. Infect Immun 1996;64(8):3127-
3133. 
177. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of 
viral replication by interferon-gamma-induced nitric oxide synthase. Science 
1993;261(5127):1445-1448. 
178. Thiemermann C, Vane J. Inhibition of nitric oxide synthesis reduces the hypotension 
induced by bacterial lipopolysaccharides in the rat in vivo. Eur J Pharmacol 
1990;182(3):591-595. 
179. Kilbourn RG, Jubran A, Gross SS, et al. Reversal of endotoxin-mediated shock by NG-
methyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 
1990;172(3):1132-1138. 
79
180. Nava E, Palmer RM, Moncada S. The role of nitric oxide in endotoxic shock: effects of 
NG-monomethyl-L-arginine. J Cardiovasc Pharmacol 1992;20 Suppl 12:S132-4. 
181. Teale DM, Atkinson AM. Inhibition of nitric oxide synthesis improves survival in a 
murine peritonitis model of sepsis that is not cured by antibiotics alone. J Antimicrob 
Chemother 1992;30(6):839-842. 
182. Evans T, Carpenter A, Silva A, Cohen J. Inhibition of nitric oxide synthase in 
experimental gram-negative sepsis. J Infect Dis 1994;169(2):343-349. 
183. Evans T, Carpenter A, Kinderman H, Cohen J. Evidence of increased nitric oxide 
production in patients with the sepsis syndrome. Circ Shock 1993;41(2):77-81. 
184. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric 
oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994;28(1):34-39. 
185. Szabo C. Alterations in nitric oxide production in various forms of circulatory shock. 
New Horiz 1995;3(1):2-32. 
186. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrite in 
synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic 
diseases. Ann Rheum Dis 1992;51(11):1219-1222. 
187. McInnes IB, Leung BP, Field M, et al. Production of nitric oxide in the synovial 
membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996;184(4):1519-1524. 
188. Grabowski PS, Wright PK, Van 't Hof RJ, Helfrich MH, Ohshima H, Ralston SH. 
Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in 
rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1997;36(6):651-655. 
189. Di Mauro D, Bitto L, D'Andrea L, et al. Behaviour of nitric oxide synthase isoforms in 
inflammatory human joint diseases: an immunohistochemical study. Ital J Anat Embryol 
2006;111(2):111-123. 
190. Cuzzocrea S, Chatterjee PK, Mazzon E, et al. Beneficial effects of GW274150, a novel, 
potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced 
arthritis. Eur J Pharmacol 2002;453(1):119-129. 
191. Pelletier J, Jovanovic D, Fernandes JC, et al. Reduction in the structural changes of 
experimental osteoarthritis by a nitric oxide inhibitor. Osteoarthritis Cartilage 
1999;7(4):416-418. 
192. Danilov AI, Jagodic M, Wiklund NP, Olsson T, Brundin L. Effects of long term NOS 
inhibition on disease and the immune system in MOG induced EAE. Nitric Oxide 
2005;13(3):188-195. 
80
193. Wilkinson-Berka JL, Kelly DJ, Koerner SM, et al. ALT-946 and aminoguanidine, 
inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic 
(mREN-2)27 rat. Diabetes 2002;51(11):3283-3289. 
194. Blix IJ, Helgeland K. LPS from Actinobacillus actinomycetemcomitans and production 
of nitric oxide in murine macrophages J774. Eur J Oral Sci 1998;106(1):576-581. 
195. Frolov I, Houri-Hadad Y, Soskolne A, Shapira L. In vivo exposure to Porphyromonas 
gingivalis up-regulates nitric oxide but suppresses tumour necrosis factor-alpha production 
by cultured macrophages. Immunology 1998;93(3):323-328. 
196. Kim SJ, Ha MS, Choi EY, Choi JI, Choi IS. Prevotella intermedia lipopolysaccharide 
stimulates release of nitric oxide by inducing expression of inducible nitric oxide synthase. J
Periodontal Res 2004;39(6):424-431. 
197. Kim SJ, Ha MS, Choi EY, Choi JI, Choi IS. Nitric oxide production and inducible nitric 
oxide synthase expression induced by Prevotella nigrescens lipopolysaccharide. FEMS 
Immunol Med Microbiol 2005;43(1):51-58. 
198. Kim SJ, Choi EY, Cho YJ, Lee JY, Choi JI, Choi IS. Surface-associated material from 
Porphyromonas gingivalis stimulates the release of nitric oxide by inducing expression of 
inducible nitric oxide synthase. Microbes Infect 2006;8(2):470-477. 
199. Kato C, Mikami M, Saito K. Nitric oxide production and iNOS mRNA expression in 
mice induced by repeated stimulation with live Fusobacterium nucleatum. Microbiol 
Immunol 2001;45(1):69-78. 
200. Sosroseno W, Barid I, Herminajeng E, Susilowati H. Nitric oxide production by a 
murine macrophage cell line (RAW264.7) stimulated with lipopolysaccharide from 
Actinobacillus actinomycetemcomitans. Oral Microbiol Immunol 2002;17(2):72-78. 
201. Sosroseno W, Herminajeng E, Bird PS, Seymour GJ. L-arginine-dependent nitric oxide 
production of a murine macrophage-like RAW 264.7 cell line stimulated with 
Porphyromonas gingivalis lipopolysaccharide. Oral Microbiol Immunol 2004;19(2):65-70. 
202. Jo WS, Yee ST, Yoon S, et al. Immunostimulating factor isolated from actinobacillus 
actinomycetemcomitans stimulates monocytes and inflammatory macrophages. Microbiol 
Immunol 2006;50(7):535-542. 
203. Shapira L, Champagne C, Van Dyke TE, Amar S. Strain-dependent activation of 
monocytes and inflammatory macrophages by lipopolysaccharide of Porphyromonas 
gingivalis. Infect Immun 1998;66(6):2736-2742. 
204. Daghigh F, Borghaei RC, Thornton RD, Bee JH. Human gingival fibroblasts produce 
nitric oxide in response to proinflammatory cytokines. J Periodontol 2002;73(4):392-400. 
205. Di Paola R, Marzocco S, Mazzon E, et al. Effect of aminoguanidine in ligature-induced 
periodontitis in rats. J Dent Res 2004;83(4):343-348. 
81
206. Lohinai Z, Benedek P, Feher E, et al. Protective effects of mercaptoethylguanidine, a 
selective inhibitor of inducible nitric oxide synthase, in ligature-induced periodontitis in the 
rat. Br J Pharmacol 1998;123(3):353-360. 
207. Lohinai Z, Szabo C. Role of nitric oxide in physiology and pathophysiology of 
periodontal tissues. Med Sci Monit 1998;4(6):1089-1095. 
208. Lohinai Z, Stachlewitz R, Virag L, Szekely AD, Hasko G, Szabo C. Evidence for 
reactive nitrogen species formation in the gingivomucosal tissue. J Dent Res 2001;80(2):470-
475. 
209. Gaspirc B, Masera A, Skaleric U. Immunolocalization of inducible nitric oxide synthase 
in localized juvenile periodontitis patients. Connect Tissue Res 2002;43(2-3):413-418. 
210. Batista AC, Silva TA, Chun JH, Lara VS. Nitric oxide synthesis and severity of human 
periodontal disease. Oral Dis 2002;8(5):254-260. 
211. Skaleric U, Gaspirc B, McCartney-Francis N, Masera A, Wahl SM. Proinflammatory 
and antimicrobial nitric oxide in gingival fluid of diabetic patients with periodontal disease. 
Infect Immun 2006;74(12):7010-7013. 
212. Di Paola R, Mazzon E, Muia C, et al. 5-Aminoisoquinolin-1(2H)-one, a water-soluble 
poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental 
periodontitis in rats. J Clin Periodontol 2007;34(2):95-102. 
213. Carossa S, Pera P, Doglio P, et al. Oral nitric oxide during plaque deposition. Eur J Clin 
Invest 2001;31(10):876-879. 
214. Nyman S, Schroeder HE, Lindhe J. Suppression of inflammation and bone resorption by 
indomethacin during experimental periodontitis in dogs. J Periodontol 1979;50(9):450-461. 
215. Williams RC, Jeffcoat MK, Wechter WJ, Johnson HG, Kaplan ML, Goldhaber P. Non-
steroidal anti-inflammatory drug treatment of periodontitis in beagles. J Periodontal Res 
1984;19(6):633-637. 
216. Williams RC, Jeffcoat MK, Kaplan ML, Goldhaber P, Johnson HG, Wechter WJ. 
Flurbiprofen: a potent inhibitor of alveolar bone resorption in beagles. Science 
1985;227(4687):640-642. 
217. Jeffcoat MK, Reddy MS, Haigh S, et al. A comparison of topical ketorolac, systemic 
flurbiprofen, and placebo for the inhibition of bone loss in adult periodontitis. J Periodontol 
1995;66(5):329-338. 
218. Paquette DW, Fiorellini JP, Martuscelli G, et al. Enantiospecific inhibition of ligature-
induced periodontitis in beagles with topical (S)-ketoprofen. J Clin Periodontol 
1997;24(8):521-528. 
82
219. Howell TH, Fiorellini J, Weber HP, Williams RC. Effect of the NSAID piroxicam, 
topically administered, on the development of gingivitis in beagle dogs. J Periodontal Res 
1991;26(3 Pt 1):180-183. 
220. Howell TH, Jeffcoat MK, Goldhaber P, et al. Inhibition of alveolar bone loss in beagles 
with the NSAID naproxen. J Periodontal Res 1991;26(6):498-501. 
221. Kornman KS, Blodgett RF, Brunsvold M, Holt SC. Effects of topical applications of 
meclofenamic acid and ibuprofen on bone loss, subgingival microbiota and gingival PMN 
response in the primate Macaca fascicularis. J Periodontal Res 1990;25(5):300-307. 
222. Reddy MS, Palcanis KG, Barnett ML, Haigh S, Charles CH, Jeffcoat MK. Efficacy of 
meclofenamate sodium (Meclomen) in the treatment of rapidly progressive periodontitis. J
Clin Periodontol 1993;20(9):635-640. 
223. Williams RC, Jeffcoat MK, Howell TH, et al. Indomethacin or flurbiprofen treatment of 
periodontitis in beagles: comparison of effect on bone loss. J Periodontal Res 
1987;22(5):403-407. 
224. Williams RC, Jeffcoat MK, Howell TH, et al. Topical flurbiprofen treatment of 
periodontitis in beagles. J Periodontal Res 1988;23(3):166-169. 
225. Williams RC, Offenbacher S, Jeffcoat MK, et al. Indomethacin or flurbiprofen treatment 
of periodontitis in beagles: effect on crevicular fluid arachidonic acid metabolites compared 
with effect on alveolar bone loss. J Periodontal Res 1988;23(2):134-138. 
226. Offenbacher S, Williams RC, Jeffcoat MK, et al. Effects of NSAIDs on beagle 
crevicular cyclooxygenase metabolites and periodontal bone loss. J Periodontal Res 
1992;27(3):207-213. 
227. Abramson MM, Wolff LF, Offenbacher S, Aeppli DM, Hardie ND, Friedman HM. 
Flurbiprofen effect on gingival crevicular fluid prostaglandin and thromboxane levels in 
humans. J Periodontal Res 1992;27(5):539-543. 
228. Paquette DW, Lawrence HP, McCombs GB, et al. Pharmacodynamic effects of 
ketoprofen on crevicular fluid prostanoids in adult periodontitis. J Clin Periodontol 
2000;27(8):558-566. 
229. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like 
drugs. Nat New Biol 1971;231(25):232-235. 
230. Salvi GE, Lang NP. The effects of non-steroidal anti-inflammatory drugs (selective and 
non-selective) on the treatment of periodontal diseases. Curr Pharm Des 2005;11(14):1757-
1769. 
231. Reddy MS, Geurs NC, Gunsolley JC. Periodontal host modulation with antiproteinase, 
anti-inflammatory, and bone-sparing agents. A systematic review. Ann Periodontol 
2003;8(1):12-37. 
83
232. Williams RC, Jeffcoat MK, Howell TH, et al. Altering the progression of human 
alveolar bone loss with the non-steroidal anti-inflammatory drug flurbiprofen. J Periodontol 
1989;60(9):485-490. 
233. Modeer T, Bengtsson A, Rolla G. Triclosan reduces prostaglandin biosynthesis in 
human gingival fibroblasts challenged with interleukin-1 in vitro. J Clin Periodontol 
1996;23(10):927-933. 
234. Mustafa M, Wondimu B, Yucel-Lindberg T, Kats-Hallstrom AT, Jonsson AS, Modeer 
T. Triclosan reduces microsomal prostaglandin E synthase-1 expression in human gingival 
fibroblasts. J Clin Periodontol 2005;32(1):6-11. 
235. Mustafa M, Bakhiet M, Wondimu B, Modeer T. Effect of triclosan on interferon-gamma 
production and major histocompatibility complex class II expression in human gingival 
fibroblasts. J Clin Periodontol 2000;27(10):733-737. 
236. Mustafa M, Wondimu B, Ibrahim M, Modeer T. Effect of triclosan on interleukin-1 beta 
production in human gingival fibroblasts challenged with tumor necrosis factor alpha. Eur J 
Oral Sci 1998;106(2 Pt 1):637-643. 
237. Delima AJ, Oates T, Assuma R, et al. Soluble antagonists to interleukin-1 (IL-1) and 
tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. J
Clin Periodontol 2001;28(3):233-240. 
238. Graves DT, Delima AJ, Assuma R, Amar S, Oates T, Cochran D. Interleukin-1 and 
tumor necrosis factor antagonists inhibit the progression of inflammatory cell infiltration 
toward alveolar bone in experimental periodontitis. J Periodontol 1998;69(12):1419-1425. 
239. Oates TW, Graves DT, Cochran DL. Clinical, radiographic and biochemical assessment 
of IL-1/TNF-alpha antagonist inhibition of bone loss in experimental periodontitis. J Clin 
Periodontol 2002;29(2):137-143. 
240. Zhang X, Kohli M, Zhou Q, Graves DT, Amar S. Short- and long-term effects of IL-1 
and TNF antagonists on periodontal wound healing. J Immunol 2004;173(5):3514-3523. 
241. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: 
effects on nitric oxide synthases. Proc Natl Acad Sci U S A 1996;93(24):14014-14019. 
242. Murrell GA, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in 
articular cartilage. Biochem Biophys Res Commun 1995;206(1):15-21. 
243. Amin AR, Patel RN, Thakker GD, Lowenstein CJ, Attur MG, Abramson SB. Post-
transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages 
by doxycycline and chemically modified tetracyclines. FEBS Lett 1997;410(2-3):259-264. 
244. Crout RJ, Lee HM, Schroeder K, et al. The "cyclic" regimen of low-dose doxycycline 
for adult periodontitis: a preliminary study. J Periodontol 1996;67(5):506-514. 
84
245. Caton JG, Ciancio SG, Blieden TM, et al. Treatment with subantimicrobial dose 
doxycycline improves the efficacy of scaling and root planing in patients with adult 
periodontitis. J Periodontol 2000;71(4):521-532. 
246.  Golub LM, McNamara TF, Ryan ME, et al. Adjunctive treatment with subantimicrobial 
doses of doxycycline: effects on gingival fluid collagenase activity and attachment loss in 
adult periodontitis. J Clin Periodontol 2001;28(2):146-156. 
247. Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline 
does not lead to changes in antimicrobial susceptibility. J Periodontol 2000;71(9):1472-1483. 
248. Golub LM, Sorsa T, Lee HM, et al. Doxycycline inhibits neutrophil (PMN)-type matrix 
metalloproteinases in human adult periodontitis gingiva. J Clin Periodontol 1995;22(2):100-
109. 
249. Cillari E, Milano S, D'Agostino P, et al. Modulation of nitric oxide production by 
tetracyclines and chemically modified tetracyclines. Adv Dent Res 1998;12(2):126-130. 
250. Patel RN, Attur MG, Dave MN, et al. A novel mechanism of action of chemically 
modified tetracyclines: inhibition of COX-2-mediated prostaglandin E2 production. J
Immunol 1999;163(6):3459-3467. 
251. Ryan ME, Ramamurthy NS, Sorsa T, Golub LM. MMP-mediated events in diabetes. 
Ann N Y Acad Sci 1999;878:311-334. 
252.  Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 
1997;53(7):576-582. 
253.  Zingarelli B, Southan GJ, Gilad E, O'Connor M, Salzman AL, Szabo C. The inhibitory 
effects of mercaptoalkylguanidines on cyclo-oxygenase activity. Br J Pharmacol 
1997;120(3):357-366. 
254. Southan GJ, Zingarelli B, O'Connor M, Salzman AL, Szabo C. Spontaneous 
rearrangement of aminoalkylisothioureas into mercaptoalkylguanidines, a novel class of 
nitric oxide synthase inhibitors with selectivity towards the inducible isoform. Br J 
Pharmacol 1996;117(4):619-632. 
255. Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, Heft MW. 
Expression of the receptor of advanced glycation end products in gingival tissues of type 2 
diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry 
and RT-PCR. J Clin Periodontol 2005;32(1):40-44. 
256. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end 
products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and 
insights into therapeutic modalities. Ann Periodontol 2001;6(1):113-118. 
85
257. Pertynska-Marczewska M, Kiriakidis S, Wait R, Beech J, Feldmann M, Paleolog EM. 
Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine 
production in human monocyte/macrophages. Cytokine 2004;28(1):35-47. 
258. Goova MT, Li J, Kislinger T, et al. Blockade of receptor for advanced glycation end-
products restores effective wound healing in diabetic mice. Am J Pathol 2001;159(2):513-
525. 
259. Santana RB, Xu L, Chase HB, Amar S, Graves DT, Trackman PC. A role for advanced 
glycation end products in diminished bone healing in type 1 diabetes. Diabetes 
2003;52(6):1502-1510. 
260. Paquette DW, Rosenberg A, Lohinai Z, et al. Inhibition of experimental gingivitis in 
beagle dogs with topical mercaptoalkylguanidines. J Periodontol 2006;77(3):385-391. 
261. Leitao RF, Ribeiro RA, Chaves HV, Rocha FA, Lima V, Brito GA. Nitric oxide 
synthase inhibition prevents alveolar bone resorption in experimental periodontitis in rats. J
Periodontol 2005;76(6):956-963. 
262. Lindhe J, Hamp S, Loe H. Experimental periodontitis in the beagle dog. J Periodontal 
Res 1973;8(1):1-10. 
263. Lindhe J, Rylander H. Experimental gingivitis in young dogs. Scand J Dent Res 
1975;83(6):314-326. 
264. Schroeder HE, Lindhe J. Conversion of stable established gingivitis in the dog into 
destructive periodontitis. Arch Oral Biol 1975;20(12):775-782. 
265. Lindhe J, Ericsson I. Effect of ligature placement and dental plaque on periodontal 
tissue breakdown in the dog. J Periodontol 1978;49(7):343-350. 
266.  Paquette DW, Waters GS, Stefanidou VL, et al. Inhibition of experimental gingivitis in 
beagle dogs with topical salivary histatins. J Clin Periodontol 1997;24(4):216-222. 
267.  PageR, Schroeder H. Periodontitis in man and other animals: A comparative review. 
New York: Basel; 1982:330. 
268.  Loe H, Thelade E, Jenson S. Experimental gingivitis in man. Journal of P 1965;36:177-
187. 
269. Radice M, Martino PA, Reiter AM. Evaluation of subgingival bacteria in the dog and 
susceptibility to commonly used antibiotics. J Vet Dent 2006;23(4):219-224. 
270. Nociti FH,Jr, Cesco De Toledo R, Machado MA, Stefani CM, Line SR, Goncalves RB. 
Clinical and microbiological evaluation of ligature-induced peri-implantitis and periodontitis 
in dogs. Clin Oral Implants Res 2001;12(4):295-300. 
86
271. Loe H, Silness J. Periodontal disease in pregnancy. I.Prevalence and severity. Acta 
Odontol Scand 1963;21:533-551. 
272. Silness J, Loe H. Periodontal disease in pregnancy. II.Correlation between oral hygiene 
and periodontal condition. Acta Odontol Scand 1964;24:747-759. 
273. Lenox JA, Kopczyk RA. A clinical system for scoring a patient's oral hygiene 
performance. J Am Dent Assoc 1973;86(4):849-852. 
274. Mombelli A, van Oosten MA, Schurch E,Jr, Land NP. The microbiota associated with 
successful or failing osseointegrated titanium implants. Oral Microbiol Immunol 
1987;2(4):145-151. 
275. Ericsson I, Lindhe J, Rylander H, Okamoto H. Experimental periodontal breakdown in 
the dog. Scand J Dent Res 1975;83(3):189-192. 
276. Rudolph DJ, White SC. Film-holding instruments for intraoral subtraction radiography. 
Oral Surg Oral Med Oral Pathol 1988;65(6):767-772. 
277. Mol A. Imaging methods in periodontology. Periodontol 2000 2004;34:34-48. 
278. Ruttimann UE, Webber RL, Schmidt E. A robust digital method for film contrast 
correction in subtraction radiography. J Periodontal Res 1986;21(5):486-495. 
279. Howell TH, Fiorellini JP, Blackburn P, Projan SJ, de la Harpe J, Williams RC. The 
effect of a mouthrinse based on nisin, a bacteriocin, on developing plaque and gingivitis in 
beagle dogs. J Clin Periodontol 1993;20(5):335-339. 
280. Carlos J, Wolfe M, Kingman A. The extent and severity index: A simple method for use 
in epidemiologic studies of periodontal disease. J Clin Periodontol 13:500-504, 1986.  
281. Knipping S, Holzhausen HJ, Berghaus A, Bloching M, Riederer A. Ultrastructural 
detection of nitric oxide in human nasal mucosa. Otolaryngol Head Neck Surg 
2005;132(4):620-625. 
282. Gilchrist M, McCauley SD, Befus AD. Expression, localization, and regulation of NOS 
in human mast cell lines: effects on leukotriene production. Blood 2004;104(2):462-469. 
283. Coleman JW. Nitric oxide: a regulator of mast cell activation and mast cell-mediated 
inflammation. Clin Exp Immunol 2002;129(1):4-10. 
284. D'Attillio M, Di Maio F, D'Arcangela C, et al. Gingival endothelial and inducible nitric 
oxide synthase levels during orthodontic treatment: a cross-sectional study. Angle Orthod 
2004;74(6):851-858. 
285. van Straaten JF, Postma DS, Coers W, Noordhoek JA, Kauffman HF, Timens W. 
Macrophages in lung tissue from patients with pulmonary emphysema express both inducible 
and endothelial nitric oxide synthase. Mod Pathol 1998;11(7):648-655. 
87
286. Caballero-Alias AM, Loveridge N, Lyon A, Das-Gupta V, Pitsillides A, Reeve J. NOS 
isoforms in adult human osteocytes: multiple pathways of NO regulation? Calcif Tissue Int 
2004;75(1):78-84. 
287. McCartney-Francis NL, Song X, Mizel DE, Wahl SM. Selective inhibition of inducible 
nitric oxide synthase exacerbates erosive joint disease. J Immunol 2001;166(4):2734-2740. 
288. Hayashi K, Igarashi K, Miyoshi K, Shinoda H, Mitani H. Involvement of nitric oxide in 
orthodontic tooth movement in rats. Am J Orthod Dentofacial Orthop 2002;122(3):306-309. 
289. Murohara T, Asahara T, Silver M, et al. Nitric oxide synthase modulates angiogenesis in 
response to tissue ischemia. J Clin Invest 1998;101(11):2567-2578. 
290. Suthin K, Matsushita K, Machigashira M, et al. Enhanced expression of vascular 
endothelial growth factor by periodontal pathogens in gingival fibroblasts. J Periodontal Res 
2003;38(1):90-96. 
291. Sakallioglu EE, Aliyev E, Lutfioglu M, Yavuz U, Acikgoz G. Vascular endothelial 
growth factor (VEGF) levels of gingiva and gingival crevicular fluid in diabetic and 
systemically healthy periodontitis patients. Clin Oral Investig 2007;
292. Guneri P, Unlu F, Yesilbek B, et al. Vascular endothelial growth factor in gingival 
tissues and crevicular fluids of diabetic and healthy periodontal patients. J Periodontol 
2004;75(1):91-97. 
293. Unlu F, Guneri PG, Hekimgil M, Yesilbek B, Boyacioglu H. Expression of vascular 
endothelial growth factor in human periodontal tissues: comparison of healthy and diabetic 
patients. J Periodontol 2003;74(2):181-187. 
294. Giannobile WV, Al-Shammari KF, Sarment DP. Matrix molecules and growth factors 
as indicators of periodontal disease activity. Periodontol 2000 2003;31:125-134. 
295. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from 
vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced 
angiogenesis. J Clin Invest 1997;99(11):2625-2634. 
296. Murohara T, Horowitz JR, Silver M, et al. Vascular endothelial growth factor/vascular 
permeability factor enhances vascular permeability via nitric oxide and prostacyclin. 
Circulation 1998;97(1):99-107. 
297. Mayhan WG. VEGF increases permeability of the blood-brain barrier via a nitric oxide 
synthase/cGMP-dependent pathway. Am J Physiol 1999;276(5 Pt 1):C1148-53. 
298. Wu HM, Huang Q, Yuan Y, Granger HJ. VEGF induces NO-dependent 
hyperpermeability in coronary venules. Am J Physiol 1996;271(6 Pt 2):H2735-9. 
299. Belenky SN, Robbins RA, Rubinstein I. Nitric oxide synthase inhibitors attenuate 
human monocyte chemotaxis in vitro. J Leukoc Biol 1993;53(5):498-503. 
88
300. Alayan J, Ivanovski S, Gemmell E, et al. Deficiency of iNOS contributes to 
Porphyromonas gingivalis-induced tissue damage. Oral Microbiol Immunol 2006;21: 360-
365. 
301. Leitao RF, Rocha FA, Chaves HV, et al. Locally applied isosorbide decreases bone 
resorption in experimental periodontitis in rats. J Periodontol 2004;75(9):1227-1232. 
 
